###begin article-title 0
APC promoter methylation and protein expression in hepatocellular carcinoma
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 80 88 <span type="species:ncbi:9606">patients</span>
We investigated the impact of promoter methylation on APC protein expression in patients with hepatocellular carcinoma (HCC).
###end p 2
###begin title 3
Materials and methods
###end title 3
###begin p 4
###xml 3 11 <span type="species:ncbi:9606">patients</span>
50 patients [HCC (n=19), liver metastasis (n=19), cholangiocellular cancer (n=7), and benign liver tumors (n=5)] were studied for methylation using Methylight analysis. APC mutation was investigated by protein truncation test and direct sequencing of genomic DNA. The protein expression was evaluated by immunohistochemistry and Western blot analysis.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 109 117 <span type="species:ncbi:9606">patients</span>
The APC promoter was hypermethylated in 81.8% of non-cancerous liver tissue samples. All HCC samples and ten patients with liver metastasis (52.6%) exhibited APC promoter methylation. The degree of methylation was significantly higher in samples from HCC compared to the non-cancerous liver tissue samples (63.1% vs. 24.98%; p=0.001). The level of APC protein expression was significantly reduced in HCC samples compared to that of the corresponding non-tumor liver tissue (p<0.05).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
Promoter methylation of the APC gene seems to be of significance in hepatocarcinogenesis and results in reduced protein expression in HCC. Interestingly, APC promoter methylation is also present in the vast majority of non-cancerous liver tissue whose (patho)physiological function remains unresolved.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1999</xref>
###xml 350 354 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2003</xref>
###xml 780 787 <span type="species:ncbi:9606">patient</span>
###xml 791 798 <span type="species:ncbi:9606">patient</span>
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and ranks as the fifth most common cancer in the world, and the third most common cause of cancer-related death (Bosch et al. 1999). More than 500,000 new cases are diagnosed annually, with an age-adjusted worldwide incidence of 5.5-14.9 per 100,000 population (Llovet et al. 2003). The pathogenesis of HCC is multifactorial. Environmental, infectious, nutritional, metabolic, and endocrine factors contribute directly or indirectly to hepatocarcinogenesis. The importance of individual factors varies geographically depending on environmental and socioeconomic influences. Synchronous occurrence of different risk factors, such as chronic viral hepatitis and aflatoxin burden or iron overload in a single patient or patient population increases the risk of developing HCC. Apart from genomic alterations, epigenetic changes such as promoter methylation, may also contribute to hepatocarcinogenesis.
###end p 11
###begin p 12
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1992</xref>
###xml 543 548 <span type="species:ncbi:9606">human</span>
Methylation of DNA is a naturally occurring process and involves covalent addition of a methyl group to the 5'-position of the cytosine ring followed by a guanine nucleotide (CpG site) (Bird 1992). Small regions of genomic DNA, called CpG islands, are often located in the promoter region of genes and are usually unmethylated in normal tissue. These regions can be methylated under pathological conditions such as tumor formation. Evidence is increasing that aberrant DNA methylation participates even in the early and precancerous stages of human carcinogenesis.
###end p 12
###begin p 13
###xml 4 30 4 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adenomatous polyposis coli</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 391 395 391 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 432 435 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 729 733 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 751 755 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2000</xref>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2002</xref>
###xml 930 933 930 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
The adenomatous polyposis coli (APC) tumor suppressor gene encodes a large protein with multiple cellular functions and interactions, including signal transduction in the Wnt-signaling pathway. Preliminary reports suggest that the APC promoter is methylated in up to 81% of patients with viral hepatitis-induced HCC using the methylation-specific polymerase chain reaction (MSP) (Lee et al. 2003; Yang et al. 2003). Inasmuch as the APC promoter has two major promoters (1A and 1B) with five alternatively spliced 5' untranslated regions in different transcripts, so far various groups have reported only methylation of the 1A promoter, while the 1B promoter has not been shown to be affected by hypermethylation (Tsuchiya et al. 2000; Esteller et al. 2000; Zysman et al. 2002). To date, however, APC protein expression has not been evaluated in these patients. Therefore, we investigated the impact of promoter methylation of the APC 1A gene promoter on the corresponding protein levels in patients with HCC.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 633 637 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2002</xref>
###xml 1098 1099 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1488 1492 1484 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1995</xref>
###xml 1562 1569 1558 1565 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1569 1648 1565 1644 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Molecular results and characteristics of patients with hepatocellular carcinoma</p>
###xml 1569 1648 1565 1644 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Molecular results and characteristics of patients with hepatocellular carcinoma</p></caption>
###xml 1648 1655 1644 1651 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Patient</th>
###xml 1655 1663 1651 1659 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Etiology</th>
###xml 1663 1679 1659 1675 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Non-tumor tissue</th>
###xml 1679 1691 1675 1687 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Tumor tissue</th>
###xml 1648 1691 1644 1687 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Etiology</th><th align="left" colspan="5">Non-tumor tissue</th><th align="left" colspan="8">Tumor tissue</th></tr>
###xml 1720 1724 1716 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1995</xref>
###xml 1691 1726 1687 1722 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>) </th>
###xml 1726 1745 1722 1741 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Methylight analysis</th>
###xml 1745 1765 1741 1761 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Immunohistochemistry</th>
###xml 1798 1802 1794 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2002</xref>
###xml 1765 1803 1761 1799 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th>
###xml 1803 1815 1799 1811 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">AFP (ng/ml) </th>
###xml 1815 1834 1811 1830 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Tumor size (in mm) </th>
###xml 1834 1844 1830 1840 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Metastasis</th>
###xml 1844 1863 1840 1859 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Methylight analysis</th>
###xml 1863 1883 1859 1879 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Immunohistochemistry</th>
###xml 1691 1883 1687 1879 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>) </th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" rowspan="2">AFP (ng/ml) </th><th align="left" rowspan="2">Tumor size (in mm) </th><th align="left" rowspan="2">Metastasis</th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th></tr>
###xml 1883 1889 1879 1885 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Result</th>
###xml 1889 1896 1885 1892 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMR (%)</th>
###xml 1896 1899 1892 1895 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">N15</th>
###xml 1899 1902 1895 1898 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C20</th>
###xml 1902 1908 1898 1904 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Result</th>
###xml 1908 1915 1904 1911 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMR (%)</th>
###xml 1915 1918 1911 1914 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">N15</th>
###xml 1918 1921 1914 1917 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C20</th>
###xml 1883 1921 1879 1917 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th></tr>
###xml 1648 1921 1644 1917 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Etiology</th><th align="left" colspan="5">Non-tumor tissue</th><th align="left" colspan="8">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>) </th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" rowspan="2">AFP (ng/ml) </th><th align="left" rowspan="2">Tumor size (in mm) </th><th align="left" rowspan="2">Metastasis</th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th></tr></thead>
###xml 1921 1951 1917 1947 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="15">Hepatocellular carcinoma (HCC)</td>
###xml 1921 1951 1917 1947 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="15">Hepatocellular carcinoma (HCC)</td></tr>
###xml 1951 1962 1947 1958 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="15">Case number</td>
###xml 1951 1962 1947 1958 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="15">Case number</td></tr>
###xml 1962 1966 1958 1962 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC1</td>
###xml 1966 1975 1962 1971 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 1975 1976 1971 1972 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1976 1984 1972 1980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1984 1988 1980 1984 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.7</td>
###xml 1988 1989 1984 1985 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1989 1990 1985 1986 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1990 1996 1986 1992 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 1996 1999 1992 1995 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">709</td>
###xml 1999 2002 1995 1998 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">140</td>
###xml 2002 2014 1998 2010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Intrahepatic</td>
###xml 2014 2022 2010 2018 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2022 2027 2018 2023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62.94</td>
###xml 2027 2028 2023 2024 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2028 2029 2024 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1962 2029 1958 2025 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC1</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">15.7</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">709</td><td char="." align="char">140</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">62.94</td><td char="." align="char">3</td><td char="." align="char">5</td></tr>
###xml 2029 2033 2025 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC2</td>
###xml 2033 2044 2029 2040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2044 2045 2040 2041 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2045 2053 2041 2049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2053 2058 2049 2054 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24.95</td>
###xml 2058 2059 2054 2055 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2059 2060 2055 2056 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2060 2070 2056 2066 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2070 2074 2066 2070 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2074 2076 2070 2072 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65</td>
###xml 2076 2078 2072 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2078 2086 2074 2082 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2086 2091 2082 2087 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25.17</td>
###xml 2091 2092 2087 2088 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2092 2093 2088 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2029 2093 2025 2089 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC2</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">24.95</td><td char="." align="char">5</td><td char="." align="char">6</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">65</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">25.17</td><td char="." align="char">2</td><td char="." align="char">5</td></tr>
###xml 2093 2097 2089 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC3</td>
###xml 2097 2112 2093 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hemochromatosis</td>
###xml 2112 2113 2108 2109 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2113 2121 2109 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2121 2126 2117 2122 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12.36</td>
###xml 2126 2127 2122 2123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2127 2128 2123 2124 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2128 2138 2124 2134 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2138 2142 2134 2138 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2142 2144 2138 2140 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">70</td>
###xml 2144 2156 2140 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Intrahepatic</td>
###xml 2156 2164 2152 2160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2164 2169 2160 2165 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.51</td>
###xml 2169 2170 2165 2166 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2170 2171 2166 2167 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2093 2171 2089 2167 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC3</td><td align="left">Hemochromatosis</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">12.36</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">70</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">23.51</td><td char="." align="char">2</td><td char="." align="char">4</td></tr>
###xml 2171 2175 2167 2171 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC4</td>
###xml 2175 2184 2171 2180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2184 2185 2180 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2185 2193 2181 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2193 2198 2189 2194 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11.63</td>
###xml 2198 2199 2194 2195 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2199 2200 2195 2196 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2200 2206 2196 2202 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 2206 2209 2202 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.6</td>
###xml 2209 2212 2205 2208 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">170</td>
###xml 2212 2222 2208 2218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Peritoneal</td>
###xml 2222 2230 2218 2226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2230 2235 2226 2231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28.97</td>
###xml 2235 2236 2231 2232 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2236 2237 2232 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2171 2237 2167 2233 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC4</td><td align="left">Alcoholic</td><td char="." align="char">3</td><td align="left">Positive</td><td char="." align="char">11.63</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">7.6</td><td char="." align="char">170</td><td align="left">Peritoneal</td><td align="left">Positive</td><td char="." align="char">28.97</td><td char="." align="char">3</td><td char="." align="char">4</td></tr>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2237 2233 2233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2237 2247 2233 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Carcinosis</td>
###xml 2247 2247 2243 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2247 2247 2243 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 2247 2247 2243 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 2247 2247 2243 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 2237 2247 2233 2243 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">Carcinosis</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr>
###xml 2247 2251 2243 2247 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC5</td>
###xml 2251 2260 2247 2256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2260 2261 2256 2257 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2261 2269 2257 2265 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2269 2274 2265 2270 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.47</td>
###xml 2274 2275 2270 2271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2275 2276 2271 2272 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2276 2282 2272 2278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 2282 2288 2278 2284 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28,235</td>
###xml 2288 2290 2284 2286 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 2290 2292 2286 2288 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2292 2300 2288 2296 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2300 2303 2296 2299 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 2303 2304 2299 2300 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2304 2305 2300 2301 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2247 2305 2243 2301 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC5</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">21.47</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">28,235</td><td char="." align="char">26</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">2</td><td char="." align="char">4</td></tr>
###xml 2305 2309 2301 2305 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC6</td>
###xml 2309 2320 2305 2316 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2320 2321 2316 2317 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2321 2329 2317 2325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2329 2333 2325 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.76</td>
###xml 2333 2334 2329 2330 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2334 2335 2330 2331 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2335 2341 2331 2337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 2341 2347 2337 2343 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14,558</td>
###xml 2347 2349 2343 2345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40</td>
###xml 2349 2351 2345 2347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2351 2359 2347 2355 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2359 2364 2355 2360 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">77.37</td>
###xml 2364 2365 2360 2361 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2365 2366 2361 2362 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2305 2366 2301 2362 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC6</td><td align="left">Cryptogenic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">1.76</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">14,558</td><td char="." align="char">40</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">77.37</td><td char="." align="char">3</td><td char="." align="char">4</td></tr>
###xml 2366 2370 2362 2366 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC7</td>
###xml 2370 2381 2366 2377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2381 2382 2377 2378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2382 2390 2378 2386 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2390 2395 2386 2391 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.91</td>
###xml 2395 2396 2391 2392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2396 2397 2392 2393 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2397 2403 2393 2399 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 2403 2409 2399 2405 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">53,462</td>
###xml 2409 2412 2405 2408 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">190</td>
###xml 2412 2414 2408 2410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2414 2422 2410 2418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2422 2427 2418 2423 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40.87</td>
###xml 2427 2428 2423 2424 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2428 2429 2424 2425 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2366 2429 2362 2425 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC7</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.91</td><td char="." align="char">3</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">53,462</td><td char="." align="char">190</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">40.87</td><td char="." align="char">0</td><td char="." align="char">0</td></tr>
###xml 2429 2433 2425 2429 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC8</td>
###xml 2433 2442 2429 2438 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2442 2443 2438 2439 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2443 2451 2439 2447 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2451 2456 2447 2452 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">39.92</td>
###xml 2456 2457 2452 2453 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2457 2458 2453 2454 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2458 2468 2454 2464 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2468 2472 2464 2468 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2472 2474 2468 2470 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 2474 2476 2470 2472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2476 2484 2472 2480 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2484 2489 2480 2485 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47.83</td>
###xml 2489 2490 2485 2486 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2490 2491 2486 2487 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2429 2491 2425 2487 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC8</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">39.92</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">25</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">47.83</td><td char="." align="char">4</td><td char="." align="char">4</td></tr>
###xml 2491 2495 2487 2491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC9</td>
###xml 2495 2506 2491 2502 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2506 2507 2502 2503 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2507 2515 2503 2511 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2515 2520 2511 2516 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.82</td>
###xml 2520 2521 2516 2517 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2521 2522 2517 2518 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2522 2528 2518 2524 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Poorly</td>
###xml 2528 2531 2524 2527 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">213</td>
###xml 2531 2534 2527 2530 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">120</td>
###xml 2534 2536 2530 2532 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2536 2544 2532 2540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2544 2549 2540 2545 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">52.46</td>
###xml 2549 2550 2545 2546 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2550 2551 2546 2547 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2491 2551 2487 2547 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC9</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">27.82</td><td char="." align="char">5</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">213</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">52.46</td><td char="." align="char">5</td><td char="." align="char">4</td></tr>
###xml 2551 2556 2547 2552 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC10</td>
###xml 2556 2565 2552 2561 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2565 2566 2561 2562 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2566 2574 2562 2570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2574 2578 2570 2574 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.45</td>
###xml 2578 2579 2574 2575 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2579 2580 2575 2576 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2580 2590 2576 2586 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2590 2594 2586 2590 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.4</td>
###xml 2594 2596 2590 2592 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">55</td>
###xml 2596 2598 2592 2594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2598 2606 2594 2602 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2606 2609 2602 2605 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 2609 2610 2605 2606 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2610 2611 2606 2607 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2551 2611 2547 2607 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC10</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">27.4</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">3</td><td char="." align="char">4</td></tr>
###xml 2611 2616 2607 2612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC11</td>
###xml 2616 2625 2612 2621 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2625 2626 2621 2622 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2626 2634 2622 2630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2634 2638 2630 2634 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.45</td>
###xml 2638 2639 2634 2635 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2639 2640 2635 2636 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2640 2644 2636 2640 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Well</td>
###xml 2644 2648 2640 2644 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2648 2650 2644 2646 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 2650 2652 2646 2648 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2652 2660 2648 2656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2660 2665 2656 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.42</td>
###xml 2665 2666 2661 2662 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2666 2667 2662 2663 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2611 2667 2607 2663 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC11</td><td align="left">Alcoholic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">2</td><td char="." align="char">4</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">22</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">23.42</td><td char="." align="char">3</td><td char="." align="char">4</td></tr>
###xml 2667 2672 2663 2668 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC12</td>
###xml 2672 2681 2668 2677 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2681 2682 2677 2678 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2682 2690 2678 2686 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2690 2695 2686 2691 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.73</td>
###xml 2695 2696 2691 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2696 2697 2692 2693 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2697 2707 2693 2703 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2707 2711 2703 2707 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.4</td>
###xml 2711 2713 2707 2709 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50</td>
###xml 2713 2724 2709 2720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lymph nodes</td>
###xml 2724 2732 2720 2728 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2732 2737 2728 2733 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">32.61</td>
###xml 2737 2738 2733 2734 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2738 2739 2734 2735 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 2667 2739 2663 2735 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC12</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">15.73</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">10.4</td><td char="." align="char">50</td><td align="left">Lymph nodes</td><td align="left">Positive</td><td char="." align="char">32.61</td><td char="." align="char">2</td><td char="." align="char">3</td></tr>
###xml 2739 2744 2735 2740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC13</td>
###xml 2744 2755 2740 2751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2755 2756 2751 2752 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2756 2764 2752 2760 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2764 2767 2760 2763 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.4</td>
###xml 2767 2769 2763 2765 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2769 2771 2765 2767 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2771 2781 2767 2777 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2781 2785 2777 2781 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2785 2787 2781 2783 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60</td>
###xml 2787 2789 2783 2785 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2789 2797 2785 2793 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2797 2802 2793 2798 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.58</td>
###xml 2802 2804 2798 2800 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2804 2806 2800 2802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2739 2806 2735 2802 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC13</td><td align="left">Cryptogenic</td><td char="." align="char">5</td><td align="left">Positive</td><td char="." align="char">6.4</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">60</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">57.58</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 2806 2811 2802 2807 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC14</td>
###xml 2811 2822 2807 2818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2822 2823 2818 2819 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 2823 2831 2819 2827 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2831 2836 2827 2832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25.25</td>
###xml 2836 2838 2832 2834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2838 2840 2834 2836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2840 2850 2836 2846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2850 2854 2846 2850 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2854 2856 2850 2852 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">55</td>
###xml 2856 2858 2852 2854 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2858 2866 2854 2862 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2866 2871 2862 2867 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62.63</td>
###xml 2871 2873 2867 2869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2873 2875 2869 2871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2806 2875 2802 2871 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC14</td><td align="left">Cryptogenic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">25.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.63</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 2875 2880 2871 2876 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC15</td>
###xml 2880 2889 2876 2885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcoholic</td>
###xml 2889 2890 2885 2886 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 2890 2898 2886 2894 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2898 2899 2894 2895 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2899 2901 2895 2897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2901 2903 2897 2899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2903 2913 2899 2909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2913 2917 2909 2913 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 2917 2919 2913 2915 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 2919 2921 2915 2917 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2921 2929 2917 2925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2929 2932 2925 2928 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 2932 2934 2928 2930 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2934 2936 2930 2932 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2875 2936 2871 2932 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC15</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">24</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 2936 2941 2932 2937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC16</td>
###xml 2941 2952 2937 2948 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 2952 2953 2948 2949 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2953 2961 2949 2957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2961 2962 2957 2958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2962 2964 2958 2960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2964 2966 2960 2962 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2966 2976 2962 2972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 2976 2982 2972 2978 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">95,468</td>
###xml 2982 2984 2978 2980 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90</td>
###xml 2984 2986 2980 2982 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 2986 2994 2982 2990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2994 2999 2990 2995 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">51.63</td>
###xml 2999 3001 2995 2997 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3001 3003 2997 2999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 2936 3003 2932 2999 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC16</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">95,468</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">51.63</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 3003 3008 2999 3004 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC17</td>
###xml 3008 3019 3004 3015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 3019 3020 3015 3016 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 3020 3028 3016 3024 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 3028 3029 3024 3025 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 3029 3031 3025 3027 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3031 3033 3027 3029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3033 3037 3029 3033 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Well</td>
###xml 3037 3041 3033 3037 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 3041 3043 3037 3039 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90</td>
###xml 3043 3045 3039 3041 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 3045 3053 3041 3049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 3053 3058 3049 3054 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">82.41</td>
###xml 3058 3060 3054 3056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3060 3062 3056 3058 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3003 3062 2999 3058 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC17</td><td align="left">Cryptogenic</td><td char="." align="char">3</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">82.41</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 3062 3067 3058 3063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC18</td>
###xml 3067 3078 3063 3074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 3078 3079 3074 3075 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 3079 3087 3075 3083 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 3087 3092 3083 3088 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.25</td>
###xml 3092 3094 3088 3090 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3094 3096 3090 3092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3096 3106 3092 3102 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Moderately</td>
###xml 3106 3110 3102 3106 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.9</td>
###xml 3110 3113 3106 3109 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">140</td>
###xml 3113 3115 3109 3111 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 3115 3123 3111 3119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 3123 3126 3119 3122 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 3126 3128 3122 3124 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3128 3130 3124 3126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3062 3130 3058 3126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC18</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">13.9</td><td char="." align="char">140</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 3130 3135 3126 3131 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HCC19</td>
###xml 3135 3146 3131 3142 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cryptogenic</td>
###xml 3146 3147 3142 3143 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 3147 3155 3143 3151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 3155 3159 3151 3155 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.95</td>
###xml 3159 3161 3155 3157 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3161 3163 3157 3159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3163 3167 3159 3163 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Well</td>
###xml 3167 3171 3163 3167 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;7.0</td>
###xml 3171 3174 3167 3170 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">120</td>
###xml 3174 3176 3170 3172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 3176 3184 3172 3180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 3184 3188 3180 3184 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62.1</td>
###xml 3188 3190 3184 3186 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3190 3192 3186 3188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">nd</td>
###xml 3130 3192 3126 3188 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HCC19</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">9.95</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.1</td><td align="left">nd</td><td align="left">nd</td></tr>
###xml 1921 3192 1917 3188 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="15">Hepatocellular carcinoma (HCC)</td></tr><tr><td align="left" colspan="15">Case number</td></tr><tr><td align="left">HCC1</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">15.7</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">709</td><td char="." align="char">140</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">62.94</td><td char="." align="char">3</td><td char="." align="char">5</td></tr><tr><td align="left">HCC2</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">24.95</td><td char="." align="char">5</td><td char="." align="char">6</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">65</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">25.17</td><td char="." align="char">2</td><td char="." align="char">5</td></tr><tr><td align="left">HCC3</td><td align="left">Hemochromatosis</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">12.36</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">70</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">23.51</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC4</td><td align="left">Alcoholic</td><td char="." align="char">3</td><td align="left">Positive</td><td char="." align="char">11.63</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">7.6</td><td char="." align="char">170</td><td align="left">Peritoneal</td><td align="left">Positive</td><td char="." align="char">28.97</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">Carcinosis</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">HCC5</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">21.47</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">28,235</td><td char="." align="char">26</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC6</td><td align="left">Cryptogenic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">1.76</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">14,558</td><td char="." align="char">40</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">77.37</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC7</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.91</td><td char="." align="char">3</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">53,462</td><td char="." align="char">190</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">40.87</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">HCC8</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">39.92</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">25</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">47.83</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left">HCC9</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">27.82</td><td char="." align="char">5</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">213</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">52.46</td><td char="." align="char">5</td><td char="." align="char">4</td></tr><tr><td align="left">HCC10</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">27.4</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC11</td><td align="left">Alcoholic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">2</td><td char="." align="char">4</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">22</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">23.42</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC12</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">15.73</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">10.4</td><td char="." align="char">50</td><td align="left">Lymph nodes</td><td align="left">Positive</td><td char="." align="char">32.61</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">HCC13</td><td align="left">Cryptogenic</td><td char="." align="char">5</td><td align="left">Positive</td><td char="." align="char">6.4</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">60</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">57.58</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC14</td><td align="left">Cryptogenic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">25.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC15</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">24</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC16</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">95,468</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">51.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC17</td><td align="left">Cryptogenic</td><td char="." align="char">3</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">82.41</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC18</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">13.9</td><td char="." align="char">140</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC19</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">9.95</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.1</td><td align="left">nd</td><td align="left">nd</td></tr></tbody>
###xml 1648 3192 1644 3188 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Etiology</th><th align="left" colspan="5">Non-tumor tissue</th><th align="left" colspan="8">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>) </th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" rowspan="2">AFP (ng/ml) </th><th align="left" rowspan="2">Tumor size (in mm) </th><th align="left" rowspan="2">Metastasis</th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th></tr></thead><tbody><tr><td align="left" colspan="15">Hepatocellular carcinoma (HCC)</td></tr><tr><td align="left" colspan="15">Case number</td></tr><tr><td align="left">HCC1</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">15.7</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">709</td><td char="." align="char">140</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">62.94</td><td char="." align="char">3</td><td char="." align="char">5</td></tr><tr><td align="left">HCC2</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">24.95</td><td char="." align="char">5</td><td char="." align="char">6</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">65</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">25.17</td><td char="." align="char">2</td><td char="." align="char">5</td></tr><tr><td align="left">HCC3</td><td align="left">Hemochromatosis</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">12.36</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">70</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">23.51</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC4</td><td align="left">Alcoholic</td><td char="." align="char">3</td><td align="left">Positive</td><td char="." align="char">11.63</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">7.6</td><td char="." align="char">170</td><td align="left">Peritoneal</td><td align="left">Positive</td><td char="." align="char">28.97</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">Carcinosis</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">HCC5</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">21.47</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">28,235</td><td char="." align="char">26</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC6</td><td align="left">Cryptogenic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">1.76</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">14,558</td><td char="." align="char">40</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">77.37</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC7</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.91</td><td char="." align="char">3</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">53,462</td><td char="." align="char">190</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">40.87</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">HCC8</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">39.92</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">25</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">47.83</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left">HCC9</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">27.82</td><td char="." align="char">5</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">213</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">52.46</td><td char="." align="char">5</td><td char="." align="char">4</td></tr><tr><td align="left">HCC10</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">27.4</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC11</td><td align="left">Alcoholic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">2</td><td char="." align="char">4</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">22</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">23.42</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC12</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">15.73</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">10.4</td><td char="." align="char">50</td><td align="left">Lymph nodes</td><td align="left">Positive</td><td char="." align="char">32.61</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">HCC13</td><td align="left">Cryptogenic</td><td char="." align="char">5</td><td align="left">Positive</td><td char="." align="char">6.4</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">60</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">57.58</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC14</td><td align="left">Cryptogenic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">25.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC15</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">24</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC16</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">95,468</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">51.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC17</td><td align="left">Cryptogenic</td><td char="." align="char">3</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">82.41</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC18</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">13.9</td><td char="." align="char">140</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC19</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">9.95</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.1</td><td align="left">nd</td><td align="left">nd</td></tr></tbody></table>
###xml 3192 3194 3188 3190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nd</italic>
###xml 3205 3208 3201 3204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AFP</italic>
###xml 3192 3226 3188 3222 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><italic>nd</italic> not done, <italic>AFP</italic> alpha fetoprotein</p>
###xml 3192 3226 3188 3222 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><italic>nd</italic> not done, <italic>AFP</italic> alpha fetoprotein</p></table-wrap-foot>
###xml 1562 3226 1558 3222 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Molecular results and characteristics of patients with hepatocellular carcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Etiology</th><th align="left" colspan="5">Non-tumor tissue</th><th align="left" colspan="8">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>) </th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" rowspan="2">AFP (ng/ml) </th><th align="left" rowspan="2">Tumor size (in mm) </th><th align="left" rowspan="2">Metastasis</th><th align="left" colspan="2">Methylight analysis</th><th align="left" colspan="2">Immunohistochemistry</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">N15</th><th align="left">C20</th></tr></thead><tbody><tr><td align="left" colspan="15">Hepatocellular carcinoma (HCC)</td></tr><tr><td align="left" colspan="15">Case number</td></tr><tr><td align="left">HCC1</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">15.7</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">709</td><td char="." align="char">140</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">62.94</td><td char="." align="char">3</td><td char="." align="char">5</td></tr><tr><td align="left">HCC2</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">24.95</td><td char="." align="char">5</td><td char="." align="char">6</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">65</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">25.17</td><td char="." align="char">2</td><td char="." align="char">5</td></tr><tr><td align="left">HCC3</td><td align="left">Hemochromatosis</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">12.36</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">70</td><td align="left">Intrahepatic</td><td align="left">Positive</td><td char="." align="char">23.51</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC4</td><td align="left">Alcoholic</td><td char="." align="char">3</td><td align="left">Positive</td><td char="." align="char">11.63</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">7.6</td><td char="." align="char">170</td><td align="left">Peritoneal</td><td align="left">Positive</td><td char="." align="char">28.97</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">Carcinosis</td><td align="left"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">HCC5</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">21.47</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">28,235</td><td char="." align="char">26</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left">HCC6</td><td align="left">Cryptogenic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">1.76</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Poorly</td><td char="." align="char">14,558</td><td char="." align="char">40</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">77.37</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC7</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.91</td><td char="." align="char">3</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">53,462</td><td char="." align="char">190</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">40.87</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">HCC8</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">39.92</td><td char="." align="char">5</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">25</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">47.83</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left">HCC9</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">27.82</td><td char="." align="char">5</td><td char="." align="char">4</td><td align="left">Poorly</td><td char="." align="char">213</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">52.46</td><td char="." align="char">5</td><td char="." align="char">4</td></tr><tr><td align="left">HCC10</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">27.4</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC11</td><td align="left">Alcoholic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">8.45</td><td char="." align="char">2</td><td char="." align="char">4</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">22</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">23.42</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left">HCC12</td><td align="left">Alcoholic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">15.73</td><td char="." align="char">4</td><td char="." align="char">5</td><td align="left">Moderately</td><td char="." align="char">10.4</td><td char="." align="char">50</td><td align="left">Lymph nodes</td><td align="left">Positive</td><td char="." align="char">32.61</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">HCC13</td><td align="left">Cryptogenic</td><td char="." align="char">5</td><td align="left">Positive</td><td char="." align="char">6.4</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">60</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">57.58</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC14</td><td align="left">Cryptogenic</td><td char="." align="char">4</td><td align="left">Positive</td><td char="." align="char">25.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">55</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC15</td><td align="left">Alcoholic</td><td char="." align="char">6</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">&lt;7.0</td><td char="." align="char">24</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC16</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">95,468</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">51.63</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC17</td><td align="left">Cryptogenic</td><td char="." align="char">3</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">90</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">82.41</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC18</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">13.25</td><td align="left">nd</td><td align="left">nd</td><td align="left">Moderately</td><td char="." align="char">13.9</td><td char="." align="char">140</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">100</td><td align="left">nd</td><td align="left">nd</td></tr><tr><td align="left">HCC19</td><td align="left">Cryptogenic</td><td char="." align="char">2</td><td align="left">Positive</td><td char="." align="char">9.95</td><td align="left">nd</td><td align="left">nd</td><td align="left">Well</td><td char="." align="char">&lt;7.0</td><td char="." align="char">120</td><td align="left">No</td><td align="left">Positive</td><td char="." align="char">62.1</td><td align="left">nd</td><td align="left">nd</td></tr></tbody></table><table-wrap-foot><p textid="18"><italic>nd</italic> not done, <italic>AFP</italic> alpha fetoprotein</p></table-wrap-foot></table-wrap>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 139 142 <span type="species:ncbi:9606">men</span>
###xml 146 151 <span type="species:ncbi:9606">women</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 757 764 <span type="species:ncbi:9606">patient</span>
###xml 874 891 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 893 896 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 999 1016 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 1018 1021 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
###xml 1062 1070 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
###xml 1291 1299 <span type="species:ncbi:9606">patients</span>
###xml 1514 1522 <span type="species:ncbi:9606">patients</span>
###xml 1610 1618 <span type="species:ncbi:9606">patients</span>
Tissue samples used in the present study were available from 50 patients who had undergone liver resection. The age of the 19 patients (15 men, 4 women) diagnosed with HCC ranged from 51 to 77 years (mean 67.1 +/- 7.2 years). Tissue samples from patients with HCC and corresponding non-neoplastic liver parenchyma had been obtained after surgery (mean tumor size 7.95 +/- 5.2 cm). The HCCs were categorized according to differentiation into well (G1; three cases), moderately (G2; eleven cases), or poorly (G3; five cases) differentiated types, which correspond, respectively, to Edmondson's Grades I/II, III, or IV (MacSween et al. 2002). In eight males patients, a regular alcohol intake of more than 60 g/day over a period of 5 years was documented. One patient was diagnosed as having hereditary hemochromatosis. In two cases a positive serology for the core protein of hepatitis B virus (HBV) ("anti-HBc antibody alone") was found without evidence of viral replication. Serological studies for hepatitis C virus (HCV) remained negative in all patients. Ten patients had cryptogenic HCC (Table 1). Locally advanced disease was found in four cases at time of liver resection. Alpha fetoprotein (AFP) serum level was available from all patients, ranging from 1.3 to 95,468 ng/ml. In eight patients AFP level remained normal during follow-up. Histologically, an advanced liver fibrosis (Ishak's fibrosis scores 3 and 4) or liver cirrhosis (Ishak's fibrosis scores 5 and 6) (Ishak et al. 1995) was diagnosed in 12 patients in the corresponding non-tumor tissue. Table 1Molecular results and characteristics of patients with hepatocellular carcinomaPatientEtiologyNon-tumor tissueTumor tissueFibrosis score (Ishak et al. 1995) Methylight analysisImmunohistochemistryDifferentiation (MacSween et al. 2002)AFP (ng/ml) Tumor size (in mm) MetastasisMethylight analysisImmunohistochemistryResultPMR (%)N15C20ResultPMR (%)N15C20Hepatocellular carcinoma (HCC)Case numberHCC1Alcoholic6Positive15.755Poorly709140IntrahepaticPositive62.9435HCC2Cryptogenic2Positive24.9556Moderately<7.065NoPositive25.1725HCC3Hemochromatosis4Positive12.3655Moderately<7.070IntrahepaticPositive23.5124HCC4Alcoholic3Positive11.6355Poorly7.6170PeritonealPositive28.9734CarcinosisHCC5Alcoholic4Positive21.4755Poorly28,23526NoPositive10024HCC6Cryptogenic6Negative1.7655Poorly14,55840NoPositive77.3734HCC7Cryptogenic2Positive13.9134Poorly53,462190NoPositive40.8700HCC8Alcoholic6Positive39.9255Moderately<7.025NoPositive47.8344HCC9Cryptogenic2Positive27.8254Poorly213120NoPositive52.4654HCC10Alcoholic6Positive8.4545Moderately27.455NoPositive10034HCC11Alcoholic2Positive8.4524Well<7.022NoPositive23.4234HCC12Alcoholic4Positive15.7345Moderately10.450Lymph nodesPositive32.6123HCC13Cryptogenic5Positive6.4ndndModerately<7.060NoPositive57.58ndndHCC14Cryptogenic4Positive25.25ndndModerately<7.055NoPositive62.63ndndHCC15Alcoholic6Negative0ndndModerately<7.024NoPositive100ndndHCC16Cryptogenic2Negative0ndndModerately95,46890NoPositive51.63ndndHCC17Cryptogenic3Negative0ndndWell<7.090NoPositive82.41ndndHCC18Cryptogenic2Positive13.25ndndModerately13.9140NoPositive100ndndHCC19Cryptogenic2Positive9.95ndndWell<7.0120NoPositive62.1ndndnd not done, AFP alpha fetoprotein
###end p 16
###begin p 17
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Molecular results and characteristics of patients with hepatocellular carcinoma
###end p 17
###begin p 18
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nd</italic>
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AFP</italic>
nd not done, AFP alpha fetoprotein
###end p 18
###begin p 19
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 179 180 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 523 524 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 554 555 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 807 808 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 832 833 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 870 871 864 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1087 1094 1081 1088 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1094 1167 1088 1161 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20">Molecular results and characteristics of patients with other liver tumors</p>
###xml 1094 1167 1088 1161 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="20">Molecular results and characteristics of patients with other liver tumors</p></caption>
###xml 1167 1174 1161 1168 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Patient</th>
###xml 1174 1202 1168 1196 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Liver disease/primary cancer</th>
###xml 1202 1218 1196 1212 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Non-tumor tissue</th>
###xml 1218 1230 1212 1224 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Tumor tissue</th>
###xml 1167 1230 1161 1224 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Liver disease/primary cancer</th><th align="left" colspan="4">Non-tumor tissue</th><th align="left" colspan="2">Tumor tissue</th></tr>
###xml 1259 1263 1253 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1995</xref>
###xml 1230 1264 1224 1258 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>)</th>
###xml 1264 1283 1258 1277 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Methylight analysis</th>
###xml 1316 1320 1310 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2002</xref>
###xml 1283 1321 1277 1315 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th>
###xml 1321 1340 1315 1334 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Methylight analysis</th>
###xml 1230 1340 1224 1334 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>)</th><th align="left" colspan="2">Methylight analysis</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" colspan="2">Methylight analysis</th></tr>
###xml 1340 1346 1334 1340 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Result</th>
###xml 1346 1353 1340 1347 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMR (%)</th>
###xml 1353 1359 1347 1353 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Result</th>
###xml 1359 1366 1353 1360 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMR (%)</th>
###xml 1340 1366 1334 1360 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">Result</th><th align="left">PMR (%)</th></tr>
###xml 1167 1366 1161 1360 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Liver disease/primary cancer</th><th align="left" colspan="4">Non-tumor tissue</th><th align="left" colspan="2">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>)</th><th align="left" colspan="2">Methylight analysis</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" colspan="2">Methylight analysis</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">Result</th><th align="left">PMR (%)</th></tr></thead>
###xml 1366 1399 1360 1393 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Cholangiocellular carcinoma (CCC)</td>
###xml 1366 1399 1360 1393 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Cholangiocellular carcinoma (CCC)</td></tr>
###xml 1399 1410 1393 1404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Case number</td>
###xml 1399 1410 1393 1404 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Case number</td></tr>
###xml 1410 1414 1404 1408 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC1</td>
###xml 1414 1423 1408 1417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bile duct</td>
###xml 1423 1424 1417 1418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 1424 1432 1418 1426 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1432 1436 1426 1430 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.57</td>
###xml 1436 1438 1430 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1438 1446 1432 1440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1446 1447 1440 1441 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1410 1447 1404 1441 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC1</td><td align="left">Bile duct</td><td align="left">6</td><td align="left">Negative</td><td char="." align="char">2.57</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1447 1451 1441 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC2</td>
###xml 1451 1460 1445 1454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bile duct</td>
###xml 1460 1461 1454 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1461 1469 1455 1463 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1469 1474 1463 1468 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.74</td>
###xml 1474 1476 1468 1470 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 1476 1484 1470 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1484 1485 1478 1479 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1447 1485 1441 1479 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC2</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">21.74</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1485 1489 1479 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC3</td>
###xml 1489 1498 1483 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bile duct</td>
###xml 1498 1499 1492 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 1499 1507 1493 1501 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1507 1511 1501 1505 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.82</td>
###xml 1511 1513 1505 1507 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 1513 1521 1507 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1521 1522 1515 1516 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1485 1522 1479 1516 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC3</td><td align="left">Bile duct</td><td align="left">2</td><td align="left">Positive</td><td char="." align="char">5.82</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1522 1526 1516 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC4</td>
###xml 1526 1535 1520 1529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bile duct</td>
###xml 1535 1536 1529 1530 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1536 1544 1530 1538 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1544 1549 1538 1543 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16.97</td>
###xml 1549 1551 1543 1545 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1551 1559 1545 1553 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1559 1563 1553 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.38</td>
###xml 1522 1563 1516 1557 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC4</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.97</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">5.38</td></tr>
###xml 1563 1567 1557 1561 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC5</td>
###xml 1567 1576 1561 1570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bile duct</td>
###xml 1576 1577 1570 1571 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1577 1585 1571 1579 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1585 1590 1579 1584 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24.38</td>
###xml 1590 1592 1584 1586 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1592 1600 1586 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1600 1601 1594 1595 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1563 1601 1557 1595 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC5</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">24.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1601 1605 1595 1599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC6</td>
###xml 1605 1617 1599 1611 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gall baldder</td>
###xml 1617 1618 1611 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 1618 1626 1612 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1626 1627 1620 1621 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1627 1629 1621 1623 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G1</td>
###xml 1629 1637 1623 1631 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1637 1638 1631 1632 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1601 1638 1595 1632 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC6</td><td align="left">Gall baldder</td><td align="left">1</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G1</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1638 1642 1632 1636 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CCC7</td>
###xml 1642 1654 1636 1648 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gall bladder</td>
###xml 1654 1655 1648 1649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1655 1663 1649 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1663 1664 1657 1658 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1664 1666 1658 1660 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1666 1674 1660 1668 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1674 1675 1668 1669 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1638 1675 1632 1669 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CCC7</td><td align="left">Gall bladder</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1675 1696 1669 1690 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Liver metastasis (M) </td>
###xml 1675 1696 1669 1690 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Liver metastasis (M) </td></tr>
###xml 1696 1707 1690 1701 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Case number</td>
###xml 1696 1707 1690 1701 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Case number</td></tr>
###xml 1707 1709 1701 1703 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M1</td>
###xml 1709 1715 1703 1709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast</td>
###xml 1715 1716 1709 1710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1716 1724 1710 1718 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1724 1728 1718 1722 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.54</td>
###xml 1728 1730 1722 1724 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1730 1738 1724 1732 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1738 1739 1732 1733 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1707 1739 1701 1733 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M1</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">9.54</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1739 1741 1733 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M2</td>
###xml 1741 1751 1735 1745 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1751 1752 1745 1746 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1752 1760 1746 1754 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1760 1765 1754 1759 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.38</td>
###xml 1765 1767 1759 1761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1767 1775 1761 1769 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1775 1776 1769 1770 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1739 1776 1733 1770 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M2</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1776 1778 1770 1772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M3</td>
###xml 1778 1788 1772 1782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1788 1789 1782 1783 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1789 1797 1783 1791 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1797 1802 1791 1796 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40.77</td>
###xml 1802 1804 1796 1798 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 1804 1812 1798 1806 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1812 1813 1806 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1776 1813 1770 1807 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M3</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">40.77</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1813 1815 1807 1809 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M4</td>
###xml 1815 1825 1809 1819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1825 1826 1819 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1826 1834 1820 1828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1834 1839 1828 1833 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26.26</td>
###xml 1839 1841 1833 1835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 1841 1849 1835 1843 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1849 1850 1843 1844 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1813 1850 1807 1844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M4</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">26.26</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1850 1852 1844 1846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M5</td>
###xml 1852 1866 1846 1860 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Nephroblastoma</td>
###xml 1866 1867 1860 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1867 1875 1861 1869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1875 1879 1869 1873 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.71</td>
###xml 1879 1881 1873 1875 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1881 1889 1875 1883 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1889 1890 1883 1884 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1850 1890 1844 1884 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M5</td><td align="left">Nephroblastoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">6.71</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1890 1892 1884 1886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M6</td>
###xml 1892 1902 1886 1896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1902 1903 1896 1897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1903 1911 1897 1905 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1911 1916 1905 1910 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20.91</td>
###xml 1916 1918 1910 1912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 1918 1926 1912 1920 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1926 1930 1920 1924 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.36</td>
###xml 1890 1930 1884 1924 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M6</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.91</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">6.36</td></tr>
###xml 1930 1932 1924 1926 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M7</td>
###xml 1932 1942 1926 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1942 1943 1936 1937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 1943 1951 1937 1945 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1951 1955 1945 1949 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.46</td>
###xml 1955 1957 1949 1951 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1957 1965 1951 1959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 1965 1966 1959 1960 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1930 1966 1924 1960 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M7</td><td align="left">Colorectal</td><td align="left">4</td><td align="left">Positive</td><td char="." align="char">5.46</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 1966 1968 1960 1962 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M8</td>
###xml 1968 1978 1962 1972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 1978 1979 1972 1973 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1979 1987 1973 1981 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 1987 1992 1981 1986 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">18.23</td>
###xml 1992 1994 1986 1988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 1994 2002 1988 1996 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2002 2006 1996 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.39</td>
###xml 1966 2006 1960 2000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M8</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">18.23</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">2.39</td></tr>
###xml 2006 2008 2000 2002 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M9</td>
###xml 2008 2018 2002 2012 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2018 2019 2012 2013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2019 2027 2013 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2027 2032 2021 2026 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">45.51</td>
###xml 2032 2034 2026 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2034 2042 2028 2036 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2042 2047 2036 2041 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69.95</td>
###xml 2006 2047 2000 2041 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M9</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">45.51</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">69.95</td></tr>
###xml 2047 2050 2041 2044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M10</td>
###xml 2050 2060 2044 2054 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2060 2061 2054 2055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2061 2069 2055 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2069 2070 2063 2064 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2070 2072 2064 2066 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2072 2080 2066 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2080 2085 2074 2079 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.65</td>
###xml 2047 2085 2041 2079 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M10</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">23.65</td></tr>
###xml 2085 2088 2079 2082 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M11</td>
###xml 2088 2095 2082 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gastric</td>
###xml 2095 2096 2089 2090 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2096 2104 2090 2098 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2104 2109 2098 2103 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.68</td>
###xml 2109 2111 2103 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 2111 2119 2105 2113 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2119 2124 2113 2118 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.74</td>
###xml 2085 2124 2079 2118 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M11</td><td align="left">Gastric</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">36.68</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">23.74</td></tr>
###xml 2124 2127 2118 2121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M12</td>
###xml 2127 2137 2121 2131 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2137 2138 2131 2132 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2138 2146 2132 2140 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2146 2151 2140 2145 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25.78</td>
###xml 2151 2153 2145 2147 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2153 2161 2147 2155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2161 2166 2155 2160 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.65</td>
###xml 2124 2166 2118 2160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M12</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">25.78</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">21.65</td></tr>
###xml 2166 2169 2160 2163 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M13</td>
###xml 2169 2179 2163 2173 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2179 2180 2173 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2180 2188 2174 2182 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2188 2193 2182 2187 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12.48</td>
###xml 2193 2195 2187 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2195 2203 2189 2197 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2203 2204 2197 2198 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2166 2204 2160 2198 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M13</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">12.48</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 2204 2207 2198 2201 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M14</td>
###xml 2207 2217 2201 2211 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2217 2218 2211 2212 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 2218 2226 2212 2220 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2226 2231 2220 2225 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22.17</td>
###xml 2231 2233 2225 2227 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2233 2241 2227 2235 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2241 2246 2235 2240 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.73</td>
###xml 2204 2246 2198 2240 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M14</td><td align="left">Colorectal</td><td align="left">1</td><td align="left">Positive</td><td char="." align="char">22.17</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">27.73</td></tr>
###xml 2246 2249 2240 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M15</td>
###xml 2249 2259 2243 2253 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2259 2260 2253 2254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2260 2268 2254 2262 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2268 2272 2262 2266 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29.5</td>
###xml 2272 2274 2266 2268 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2274 2282 2268 2276 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2282 2287 2276 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.92</td>
###xml 2246 2287 2240 2281 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M15</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">29.5</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">57.92</td></tr>
###xml 2287 2290 2281 2284 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M16</td>
###xml 2290 2300 2284 2294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2300 2301 2294 2295 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2301 2309 2295 2303 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2309 2314 2303 2308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16.95</td>
###xml 2314 2316 2308 2310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2316 2324 2310 2318 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2324 2325 2318 2319 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2287 2325 2281 2319 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M16</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.95</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr>
###xml 2325 2328 2319 2322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M17</td>
###xml 2328 2334 2322 2328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast</td>
###xml 2334 2335 2328 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2335 2343 2329 2337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2343 2348 2337 2342 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.85</td>
###xml 2348 2350 2342 2344 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2350 2358 2344 2352 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2358 2363 2352 2357 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30.51</td>
###xml 2325 2363 2319 2357 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M17</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">15.85</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">30.51</td></tr>
###xml 2363 2366 2357 2360 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M18</td>
###xml 2366 2376 2360 2370 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2376 2377 2370 2371 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2377 2385 2371 2379 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2385 2390 2379 2384 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42.59</td>
###xml 2390 2392 2384 2386 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G3</td>
###xml 2392 2400 2386 2394 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2400 2405 2394 2399 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.44</td>
###xml 2363 2405 2357 2399 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M18</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42.59</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">21.44</td></tr>
###xml 2405 2408 2399 2402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M19</td>
###xml 2408 2418 2402 2412 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colorectal</td>
###xml 2418 2419 2412 2413 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2419 2427 2413 2421 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2427 2428 2421 2422 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2428 2430 2422 2424 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G2</td>
###xml 2430 2438 2424 2432 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2438 2442 2432 2436 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.57</td>
###xml 2405 2442 2399 2436 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">M19</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">7.57</td></tr>
###xml 2442 2465 2436 2459 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Benign liver tumor (B) </td>
###xml 2442 2465 2436 2459 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Benign liver tumor (B) </td></tr>
###xml 2465 2476 2459 2470 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="8">Case number</td>
###xml 2465 2476 2459 2470 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="8">Case number</td></tr>
###xml 2476 2478 2470 2472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B1</td>
###xml 2478 2481 2472 2475 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FNH</td>
###xml 2481 2482 2475 2476 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2482 2490 2476 2484 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Negative</td>
###xml 2490 2494 2484 2488 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.52</td>
###xml 2494 2496 2488 2490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">na</td>
###xml 2496 2504 2490 2498 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2504 2509 2498 2503 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24.09</td>
###xml 2476 2509 2470 2503 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B1</td><td align="left">FNH</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">3.52</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">24.09</td></tr>
###xml 2509 2511 2503 2505 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B2</td>
###xml 2511 2514 2505 2508 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FNH</td>
###xml 2514 2515 2508 2509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2515 2523 2509 2517 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2523 2525 2517 2519 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 2525 2527 2519 2521 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">na</td>
###xml 2527 2535 2521 2529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2535 2540 2529 2534 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69.82</td>
###xml 2509 2540 2503 2534 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B2</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">69.82</td></tr>
###xml 2540 2542 2534 2536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B3</td>
###xml 2542 2545 2536 2539 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FNH</td>
###xml 2545 2546 2539 2540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2546 2554 2540 2548 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2554 2558 2548 2552 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20.6</td>
###xml 2558 2560 2552 2554 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">na</td>
###xml 2560 2568 2554 2562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2568 2573 2562 2567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.29</td>
###xml 2540 2573 2534 2567 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B3</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.6</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">67.29</td></tr>
###xml 2573 2575 2567 2569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B4</td>
###xml 2575 2578 2569 2572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FNH</td>
###xml 2578 2579 2572 2573 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2579 2587 2573 2581 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2587 2592 2581 2586 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.96</td>
###xml 2592 2594 2586 2588 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">na</td>
###xml 2594 2602 2588 2596 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2602 2607 2596 2601 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.24</td>
###xml 2573 2607 2567 2601 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B4</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.96</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">15.24</td></tr>
###xml 2607 2609 2601 2603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B5</td>
###xml 2609 2624 2603 2618 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hepatic adenoma</td>
###xml 2624 2625 2618 2619 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 2625 2633 2619 2627 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2633 2638 2627 2632 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30.13</td>
###xml 2638 2640 2632 2634 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">na</td>
###xml 2640 2648 2634 2642 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Positive</td>
###xml 2648 2653 2642 2647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79.45</td>
###xml 2607 2653 2601 2647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">B5</td><td align="left">Hepatic adenoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">30.13</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">79.45</td></tr>
###xml 1366 2653 1360 2647 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="8">Cholangiocellular carcinoma (CCC)</td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">CCC1</td><td align="left">Bile duct</td><td align="left">6</td><td align="left">Negative</td><td char="." align="char">2.57</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC2</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">21.74</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC3</td><td align="left">Bile duct</td><td align="left">2</td><td align="left">Positive</td><td char="." align="char">5.82</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC4</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.97</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">5.38</td></tr><tr><td align="left">CCC5</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">24.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC6</td><td align="left">Gall baldder</td><td align="left">1</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G1</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC7</td><td align="left">Gall bladder</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left" colspan="8">Liver metastasis (M) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">M1</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">9.54</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M2</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M3</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">40.77</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M4</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">26.26</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M5</td><td align="left">Nephroblastoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">6.71</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M6</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.91</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">6.36</td></tr><tr><td align="left">M7</td><td align="left">Colorectal</td><td align="left">4</td><td align="left">Positive</td><td char="." align="char">5.46</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M8</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">18.23</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">2.39</td></tr><tr><td align="left">M9</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">45.51</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">69.95</td></tr><tr><td align="left">M10</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">23.65</td></tr><tr><td align="left">M11</td><td align="left">Gastric</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">36.68</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">23.74</td></tr><tr><td align="left">M12</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">25.78</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">21.65</td></tr><tr><td align="left">M13</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">12.48</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M14</td><td align="left">Colorectal</td><td align="left">1</td><td align="left">Positive</td><td char="." align="char">22.17</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">27.73</td></tr><tr><td align="left">M15</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">29.5</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">57.92</td></tr><tr><td align="left">M16</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.95</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M17</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">15.85</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">30.51</td></tr><tr><td align="left">M18</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42.59</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">21.44</td></tr><tr><td align="left">M19</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">7.57</td></tr><tr><td align="left" colspan="8">Benign liver tumor (B) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">B1</td><td align="left">FNH</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">3.52</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">24.09</td></tr><tr><td align="left">B2</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">69.82</td></tr><tr><td align="left">B3</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.6</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">67.29</td></tr><tr><td align="left">B4</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.96</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">15.24</td></tr><tr><td align="left">B5</td><td align="left">Hepatic adenoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">30.13</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">79.45</td></tr></tbody>
###xml 1167 2653 1161 2647 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Liver disease/primary cancer</th><th align="left" colspan="4">Non-tumor tissue</th><th align="left" colspan="2">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>)</th><th align="left" colspan="2">Methylight analysis</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" colspan="2">Methylight analysis</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">Result</th><th align="left">PMR (%)</th></tr></thead><tbody><tr><td align="left" colspan="8">Cholangiocellular carcinoma (CCC)</td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">CCC1</td><td align="left">Bile duct</td><td align="left">6</td><td align="left">Negative</td><td char="." align="char">2.57</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC2</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">21.74</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC3</td><td align="left">Bile duct</td><td align="left">2</td><td align="left">Positive</td><td char="." align="char">5.82</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC4</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.97</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">5.38</td></tr><tr><td align="left">CCC5</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">24.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC6</td><td align="left">Gall baldder</td><td align="left">1</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G1</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC7</td><td align="left">Gall bladder</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left" colspan="8">Liver metastasis (M) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">M1</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">9.54</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M2</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M3</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">40.77</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M4</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">26.26</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M5</td><td align="left">Nephroblastoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">6.71</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M6</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.91</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">6.36</td></tr><tr><td align="left">M7</td><td align="left">Colorectal</td><td align="left">4</td><td align="left">Positive</td><td char="." align="char">5.46</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M8</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">18.23</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">2.39</td></tr><tr><td align="left">M9</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">45.51</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">69.95</td></tr><tr><td align="left">M10</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">23.65</td></tr><tr><td align="left">M11</td><td align="left">Gastric</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">36.68</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">23.74</td></tr><tr><td align="left">M12</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">25.78</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">21.65</td></tr><tr><td align="left">M13</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">12.48</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M14</td><td align="left">Colorectal</td><td align="left">1</td><td align="left">Positive</td><td char="." align="char">22.17</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">27.73</td></tr><tr><td align="left">M15</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">29.5</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">57.92</td></tr><tr><td align="left">M16</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.95</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M17</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">15.85</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">30.51</td></tr><tr><td align="left">M18</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42.59</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">21.44</td></tr><tr><td align="left">M19</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">7.57</td></tr><tr><td align="left" colspan="8">Benign liver tumor (B) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">B1</td><td align="left">FNH</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">3.52</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">24.09</td></tr><tr><td align="left">B2</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">69.82</td></tr><tr><td align="left">B3</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.6</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">67.29</td></tr><tr><td align="left">B4</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.96</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">15.24</td></tr><tr><td align="left">B5</td><td align="left">Hepatic adenoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">30.13</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">79.45</td></tr></tbody></table>
###xml 2653 2656 2647 2650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FNH</italic>
###xml 2653 2682 2647 2676 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21"><italic>FNH</italic> focal nodular hyperplasia</p>
###xml 2653 2682 2647 2676 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21"><italic>FNH</italic> focal nodular hyperplasia</p></table-wrap-foot>
###xml 1087 2682 1081 2676 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="20">Molecular results and characteristics of patients with other liver tumors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Patient</th><th align="left" rowspan="3">Liver disease/primary cancer</th><th align="left" colspan="4">Non-tumor tissue</th><th align="left" colspan="2">Tumor tissue</th></tr><tr><th align="left" rowspan="2">Fibrosis score (Ishak et al. <xref ref-type="bibr" rid="CR10">1995</xref>)</th><th align="left" colspan="2">Methylight analysis</th><th align="left" rowspan="2">Differentiation (MacSween et al. <xref ref-type="bibr" rid="CR17">2002</xref>)</th><th align="left" colspan="2">Methylight analysis</th></tr><tr><th align="left">Result</th><th align="left">PMR (%)</th><th align="left">Result</th><th align="left">PMR (%)</th></tr></thead><tbody><tr><td align="left" colspan="8">Cholangiocellular carcinoma (CCC)</td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">CCC1</td><td align="left">Bile duct</td><td align="left">6</td><td align="left">Negative</td><td char="." align="char">2.57</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC2</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">21.74</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC3</td><td align="left">Bile duct</td><td align="left">2</td><td align="left">Positive</td><td char="." align="char">5.82</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC4</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.97</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">5.38</td></tr><tr><td align="left">CCC5</td><td align="left">Bile duct</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">24.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC6</td><td align="left">Gall baldder</td><td align="left">1</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G1</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">CCC7</td><td align="left">Gall bladder</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left" colspan="8">Liver metastasis (M) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">M1</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">9.54</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M2</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.38</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M3</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">40.77</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M4</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">26.26</td><td align="left">G3</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M5</td><td align="left">Nephroblastoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">6.71</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M6</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.91</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">6.36</td></tr><tr><td align="left">M7</td><td align="left">Colorectal</td><td align="left">4</td><td align="left">Positive</td><td char="." align="char">5.46</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M8</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">18.23</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">2.39</td></tr><tr><td align="left">M9</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">45.51</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">69.95</td></tr><tr><td align="left">M10</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">23.65</td></tr><tr><td align="left">M11</td><td align="left">Gastric</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">36.68</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">23.74</td></tr><tr><td align="left">M12</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">25.78</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">21.65</td></tr><tr><td align="left">M13</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">12.48</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M14</td><td align="left">Colorectal</td><td align="left">1</td><td align="left">Positive</td><td char="." align="char">22.17</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">27.73</td></tr><tr><td align="left">M15</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">29.5</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">57.92</td></tr><tr><td align="left">M16</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">16.95</td><td align="left">G2</td><td align="left">Negative</td><td char="." align="char">0</td></tr><tr><td align="left">M17</td><td align="left">Breast</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">15.85</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">30.51</td></tr><tr><td align="left">M18</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42.59</td><td align="left">G3</td><td align="left">Positive</td><td char="." align="char">21.44</td></tr><tr><td align="left">M19</td><td align="left">Colorectal</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">0</td><td align="left">G2</td><td align="left">Positive</td><td char="." align="char">7.57</td></tr><tr><td align="left" colspan="8">Benign liver tumor (B) </td></tr><tr><td align="left" colspan="8">Case number</td></tr><tr><td align="left">B1</td><td align="left">FNH</td><td align="left">0</td><td align="left">Negative</td><td char="." align="char">3.52</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">24.09</td></tr><tr><td align="left">B2</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">42</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">69.82</td></tr><tr><td align="left">B3</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">20.6</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">67.29</td></tr><tr><td align="left">B4</td><td align="left">FNH</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">27.96</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">15.24</td></tr><tr><td align="left">B5</td><td align="left">Hepatic adenoma</td><td align="left">0</td><td align="left">Positive</td><td char="." align="char">30.13</td><td align="left">na</td><td align="left">Positive</td><td char="." align="char">79.45</td></tr></tbody></table><table-wrap-foot><p textid="21"><italic>FNH</italic> focal nodular hyperplasia</p></table-wrap-foot></table-wrap>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 76 79 <span type="species:ncbi:9606">men</span>
###xml 84 89 <span type="species:ncbi:9606">women</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
###xml 1135 1143 <span type="species:ncbi:9606">patients</span>
Tissue samples were also obtained by surgical resection from 19 patients (8 men, 11 women) with liver metastases [colorectal (n = 15), gastric (n = 1), renal (n = 1), and breast (n = 2) cancer]. The age of patients ranged from 32 to 82 years (mean 63.5 +/- 14.2 years). The liver metastases were also categorized according to differentiation into well (G1; no case), moderately (G2; fifteen cases), or poorly (G3; four cases) differentiated carcinomas. Tissue samples were also obtained from seven patients with bile duct (n = 5) or gall bladder cancer (n = 2): (G1; one case), moderately (G2; four cases), or poorly (G3; two cases). The age of patients ranged from 42 to 71 years (mean 57.4 +/- 12.2 years). Five patients (mean age 40.4 +/- 14.6 years) with benign liver tumors [focal nodular hyperplasia (n = 4) or liver adenoma (n = 1)] were also investigated (Table 2). Corresponding non-tumorous liver parenchyma, as confirmed histologically, was also evaluated in all non-HCC cases. This study was approved by the Ethics Committee of the Otto-von-Guericke University of Magdeburg. Table 2Molecular results and characteristics of patients with other liver tumorsPatientLiver disease/primary cancerNon-tumor tissueTumor tissueFibrosis score (Ishak et al. 1995)Methylight analysisDifferentiation (MacSween et al. 2002)Methylight analysisResultPMR (%)ResultPMR (%)Cholangiocellular carcinoma (CCC)Case numberCCC1Bile duct6Negative2.57G2Negative0CCC2Bile duct0Positive21.74G3Negative0CCC3Bile duct2Positive5.82G3Negative0CCC4Bile duct0Positive16.97G2Positive5.38CCC5Bile duct0Positive24.38G2Negative0CCC6Gall baldder1Negative0G1Negative0CCC7Gall bladder0Negative0G2Negative0Liver metastasis (M) Case numberM1Breast0Positive9.54G2Negative0M2Colorectal0Positive27.38G2Negative0M3Colorectal0Positive40.77G3Negative0M4Colorectal0Positive26.26G3Negative0M5Nephroblastoma0Positive6.71G2Negative0M6Colorectal0Positive20.91G3Positive6.36M7Colorectal4Positive5.46G2Negative0M8Colorectal0Positive18.23G2Negative2.39M9Colorectal0Positive45.51G2Positive69.95M10Colorectal0Negative0G2Positive23.65M11Gastric0Positive36.68G3Positive23.74M12Colorectal0Positive25.78G2Positive21.65M13Colorectal0Positive12.48G2Negative0M14Colorectal1Positive22.17G2Positive27.73M15Colorectal0Positive29.5G2Positive57.92M16Colorectal0Positive16.95G2Negative0M17Breast0Positive15.85G2Positive30.51M18Colorectal0Positive42.59G3Positive21.44M19Colorectal0Negative0G2Positive7.57Benign liver tumor (B) Case numberB1FNH0Negative3.52naPositive24.09B2FNH0Positive42naPositive69.82B3FNH0Positive20.6naPositive67.29B4FNH0Positive27.96naPositive15.24B5Hepatic adenoma0Positive30.13naPositive79.45FNH focal nodular hyperplasia
###end p 19
###begin p 20
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Molecular results and characteristics of patients with other liver tumors
###end p 20
###begin p 21
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FNH</italic>
FNH focal nodular hyperplasia
###end p 21
###begin title 22
DNA extraction
###end title 22
###begin p 23
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
Genomic DNA was extracted from frozen tissue samples using the proteinase K digestion as previously reported (Ebert et al. 2003).
###end p 23
###begin title 24
Sodium bisulfite modification
###end title 24
###begin p 25
###xml 475 476 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Five mug of genomic DNA was heat-denatured for 6 min at 97degreesC, followed by incubation with 0.2 mol/l NaOH for 10 min at room temperature. The denatured DNA was treated with 3.5 mol/l sodium bisulfite and 1 mmol/l hydroquinone (pH 5.0) for 16 h at 55degreesC. The reaction mixture was purified with a gel extraction kit, and desulfhonated with 0.3 mol/l NaOH for 10 min at room temperature. The DNA was then precipitated with three volumes of cold ethanol, dissolved in H2O, and stored at -20degreesC.
###end p 25
###begin title 26
Methylight analysis of the APC gene
###end title 26
###begin p 27
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2000</xref>
###xml 530 534 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 917 921 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 1249 1253 1246 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2000</xref>
###xml 1542 1543 1537 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1754 1758 1749 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2000</xref>
###xml 1761 1767 1756 1762 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1783 1786 1778 1781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1856 1859 1851 1854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1975 1985 1970 1980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 1990 1994 1985 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 2011 2022 2006 2017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">highlighted</italic>
###xml 1767 2022 1762 2017 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Sequence of the <italic>APC</italic> 1A Promoter. A portion of bisulfite reverse complement strand of the <italic>APC</italic> gene promoter (NM_000038) is given with the primer and probe location which were used for the Methylight analysis (<italic>underlined</italic> and <italic>bold</italic>). CpG sites are <italic>highlighted</italic></p>
###xml 1767 2022 1762 2017 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Sequence of the <italic>APC</italic> 1A Promoter. A portion of bisulfite reverse complement strand of the <italic>APC</italic> gene promoter (NM_000038) is given with the primer and probe location which were used for the Methylight analysis (<italic>underlined</italic> and <italic>bold</italic>). CpG sites are <italic>highlighted</italic></p></caption>
###xml 2022 2022 2017 2017 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig1_HTML" id="MO2"/>
###xml 1761 2022 1756 2017 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="28">Sequence of the <italic>APC</italic> 1A Promoter. A portion of bisulfite reverse complement strand of the <italic>APC</italic> gene promoter (NM_000038) is given with the primer and probe location which were used for the Methylight analysis (<italic>underlined</italic> and <italic>bold</italic>). CpG sites are <italic>highlighted</italic></p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig1_HTML" id="MO2"/></fig>
###xml 635 640 <span type="species:ncbi:9606">human</span>
Genomic DNA of all samples was analyzed by the Methylight technique after bisulfite conversion as previously reported (Eads et al. 2000). In this analysis three oligonucleotids were used in every reactions. Two locus-specific PCR primers flanked an oligonucleotide probe with a 5' fluorescent reported dye (6FAM) and a 3' quencher dye (BHQ-1). Oligonucleotide primers and probes were specifically designed to bind to bisulfite-converted DNA. The gene of interest was then amplified and normalized to a reference set (beta-actin = ACTB) to normalize for input DNA. The specificity of the reactions for methylated DNA is confirmed using human unmethylated sperm DNA and CpGenome Universal Methylated DNA [(Chemicon (subsidiary or Serologicals) catalog no. S7821)]. TaqMan PCR reactions were performed in parallel with primers specific for the bisulfite-converted methylated sequence for a particular locus and with the ACTB reference primers. The ratio between the values was calculated in these two TaqMan analyses. The extent of methylation at a specific locus was determined by the following formula:  A cut-off value of 4% gave the best discrimination between normal and cancerous samples, as previously reported in esophageal cancer (Eads et al. 2000). In our study, samples with a percentage of methylation reference (PMR) of >/=4% fully methylated molecules were termed methylated, whereas samples with a PMR of <4% were considered unmethylated. The primer and probe sequences for APC promoter 1A (GeneBank accession number U02509, Fig. 1) were: forward primer (5'-3'): GAACCAAAACGCTCCCCAT; reverse primer (5'-3'): TTATATGT CGGTTACGTGCGTTTATAT; probe sequence (5'-3'): 6FAM-CCCGTCGAAAAC CCGCCGATTA-BHQ1 were used as previously reported (Eads et al. 2000). Fig. 1Sequence of the APC 1A Promoter. A portion of bisulfite reverse complement strand of the APC gene promoter (NM_000038) is given with the primer and probe location which were used for the Methylight analysis (underlined and bold). CpG sites are highlighted
###end p 27
###begin p 28
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 208 218 208 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 244 255 244 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">highlighted</italic>
Sequence of the APC 1A Promoter. A portion of bisulfite reverse complement strand of the APC gene promoter (NM_000038) is given with the primer and probe location which were used for the Methylight analysis (underlined and bold). CpG sites are highlighted
###end p 28
###begin title 29
Mutation analysis of the APC gene
###end title 29
###begin p 30
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2002</xref>
###xml 751 754 751 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 1145 1149 <span type="species:ncbi:9925">goat</span>
###xml 1155 1160 <span type="species:ncbi:10090">mouse</span>
The mutation cluster region of the APC was analyzed by a non-radioactive protein truncation test (PTT) in 12 patients with HCC as previously described (Kahmann et al. 2002). Briefly, the region was amplified by PCR from the genomic DNA in two overlapping fragments. The used primers include the sequence motifs, which are necessary for the in vitro transcription and translation, and the sequences, which code for the haemagglutinin (HA) protein motif, which serves as an immuno-tag in the following Western blot detection. The PCR results in two overlapping products: APC I corresponding to sequence position 3283 through 4683 (codon 1089 through 1555) and APC II corresponding to sequence position 4573 through 5970 (codon 1515 through 1984) of the APC gene. Next, the PCR fragments were transcribed and translated in a one-tube reaction by using commercial reagents and following the protocol of the supplier (Promega, Mannheim, Germany). The reaction products were separated by electrophoresis on a 12.5% SDS-polyacrylamide gel and electroblotted. The membrane was incubated with monoclonal anti-HA tag antibody as the first and HRP-coupled goat-anti mouse antibody as the second antibody. Detection was performed by enhanced chemoluminescence (ECL) using commercial reagents. All primer sequences and the exact conditions for PCR and the in vitro transcription and translation are available upon request.
###end p 30
###begin title 31
Western blot analysis
###end title 31
###begin p 32
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 1164 1169 <span type="species:ncbi:9606">human</span>
###xml 1322 1328 <span type="species:ncbi:9986">rabbit</span>
Frozen tissue from non-tumorous liver parenchyma and HCC obtained from three patients were homogenized in lysis buffer containing 1 mM EDTA, 50 mM beta-glycerophosphate, 2 mM sodium orthovanadate, 1% Triton-100, 10% glycerol, 1 mM DTT, and protease inhibitors (10 mg/ml benzamidine, 2 mg/ml anti-pain, and 1 mg/ml leupeptin). The protein concentration of the supernatants was determined by the BCA assay (Bio-Rad, Hercules, CA, USA). Twenty micrograms of protein in each sample was adjusted to Laemmli buffer [2% SDS, 10% glycerol, 62.5 mM Tris-HCl (pH 6.8), 100 mM DTT, and 0.1% bromphenol blue], denatured by heating at 95degreesC for 5 min, and subsequently separated on 5% polyacrylamide gels by SDS-gel electrophoresis. After separation, the proteins were transferred onto immunoblot polyvinylidene difluoride membrane (Bio-Rad). The membrane was blocked in 5% skimmed milk in 1% TBST for 1 h at room temperature, and then incubated separately with anti-APC-N15 antibody or anti-APC-C20 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4degreesC (dilution 1:200). These two antibodies react with the N-terminal and C-terminal part of the human APC protein, respectively. Membranes were then washed three times in Tris-buffered saline/0.1% Tween 20, incubated for 2 h with peroxidase-labeled anti-rabbit IgG (1:2,500, KPL) and diluted in blocking solution. Membrane-bound secondary antibodies were detected by an enhanced chemiluminescence method following the instructions of the manufacturer (ECL plus Western blotting detection reagents, Amersham Biosciences, Piscataway, NJ, USA). The membrane images were evaluated for the quantification of the protein expression, using the GeneGnome and GeneTools image scanning and analysis package (Syngene BioImaging Systems, Synoptics Ltd., Frederick, MD, USA).
###end p 32
###begin title 33
Immunohistochemistry
###end title 33
###begin p 34
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 523 529 <span type="species:ncbi:9986">rabbit</span>
###xml 560 566 <span type="species:ncbi:9986">rabbit</span>
###xml 702 708 <span type="species:ncbi:9986">rabbit</span>
Tissue samples from HCCs and corresponding non-neoplastic liver parenchyma were studied by immunohistochemistry. Deparaffinized sections were stained using hematoxylin and eosin (H&E). For immunostaining of paraffin-embedded sections, the slides were deparaffinized in xylol and rehydrated in a graded alcohol series. Endogenous biotin was blocked using the Avidin/Biotin Blocking kit (2 x 15 min; Vector Laboratories Inc., Burlingame, CA, USA). Immunostaining was performed with two antibodies directed against human APC (rabbit-anti-APC-N15, dilution 1:200; rabbit-anti-APC-C20, dilution 1:20). Incubation with the primary antibodies was performed in a moist chamber at 37degreesC for 1 h. Gout anti-rabbit IgG (30 min, room temperature; Vector Laboratories Inc.) served as a secondary antibody. Slides were washed between steps with Tris-buffered saline. Immunoreactions were visualized via an streptavidin-biotin complex, using the Vectastain ABC alkaline phosphatase kit (distributed by CAMON, Wiesbaden, Germany). FastRed (Zytomed, Berlin, Germany) served as chromogen. The specimens were counter-stained with hematoxylin. Omission of primary antibodies served as a negative control.
###end p 34
###begin title 35
Immunoreactivity score (IRS)
###end title 35
###begin p 36
###xml 588 610 588 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">immunoreactivity score</italic>
###xml 894 897 894 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
For the quantification of the immunohistochemical results, a numerical scoring system was applied. The observed expression of APC in hepatocytes and tumor cells was assessed using two categories. Category A documented the number of immunoreactive epithelial cells as 0 (no immunoreactive cells), 1 (<10%), 2 (11-50%), and 3 (>50%). A positive case was defined as having a category A value of 1. Category B documented the intensity of the immunostaining as 0 (no immunostaining), 1 (weak), 2 (moderate), and 3 (strong). Finally, the values for category A and B were added to construct an "immunoreactivity score" (IRS), which could range from 0 to 6. Note that the method of calculating the IRS does not allow the individual categories to add up to an IRS of 1. The immunostaining was performed and analyzed by an experienced GI pathologist (CR) who was blinded to the methylation status of the APC gene.
###end p 36
###begin title 37
Statistical analysis
###end title 37
###begin p 38
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2000</xref>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The PMR values of the Methylight assays were dichotomized for statistical purposes as reported previously (Eads et al. 2000). The PMR values of tumor and non-tumor samples were compared by Kolmogorov-Smirnov test, and a P < 0.05 was considered statistically significant.
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
APC promoter methylation in liver cancer
###end title 40
###begin p 41
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1A APC</italic>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 692 693 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 879 880 879 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1252 1253 1252 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
###xml 1204 1212 <span type="species:ncbi:9606">patients</span>
Using the Methylight assay, the methylation status of the 1A APC promoter was evaluated in 19 HCCs and the corresponding non-tumor liver samples. All patients with HCC and 15 of the 19 non-tumorous liver samples (79%) exhibited a PMR >4%. The mean PMR was 63.10 (range from 23.41 to 100) in the HCC and 14.19 (range from 0 to 39.92) in the non-tumor samples (Table 1). The difference between tumor and non-cancerous samples was statistically significant (P = 0.001). Even after extraction of the non-tumor samples with a PMR <4% which were classified as not methylated, the degree of methylation in HCC was significantly higher compared to the non-cancerous tissue samples (63.1% vs. 25.12%; P = 0.001). There was no difference between cirrhotic and non-cirrhotic samples regarding AFP levels, degree of methylation or protein expression evaluated by immunohistochemistry (Table 1). No correlation was found between the size and differentiation of HCC and AFP level, grade of fibrosis or presence of metastasis. Also, the grade of promoter methylation was not significantly different in samples from patients with large tumor or liver cirrhosis compared to those samples obtained from smaller cancers or patients without advanced liver fibrosis (Table 1).
###end p 41
###begin title 42
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
APC promoter methylation in other liver tumors
###end title 42
###begin p 43
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 654 657 654 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 851 852 851 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1470 1471 1470 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1658 1661 1658 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1796 1799 1796 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
###xml 1848 1856 <span type="species:ncbi:9606">patients</span>
We then assessed the frequency of APC promoter methylation in 19 liver metastases and compared it to the corresponding non-tumor liver samples (Table 2). Our analysis showed promoter methylation in eight metastases of colorectal cancers (50%), in one gastric and one breast cancer metastasis. Altogether, 52.6% of metastatic tissue samples were found to be hypermethylated. About 17 of the 19 non-tumor liver samples (89.5%) also showed promoter hypermethylation. The mean PMR was 21.19 (range 0-45.51) in the liver metastases and 15.41 (range 0-69.95) in the non-tumor tissue samples. Next, we assessed the frequency of promoter hypermethylation of the APC gene in seven patients with cholangiocarcinoma and found only one tumor with methylated promoter. Four of the seven non-tumor liver samples (57.2%) also showed promoter hypermethylation (Table 2). The mean PMR was 10.27 (range 0-24.38) in the non-tumor tissue samples. Nine of the ten tissue samples obtained from patients with benign liver tumors were found to be hypermethylated with a mean PMR of 38.01 (range from 3.52 to 79.45). Altogether, 45 of the 55 non-cancerous liver samples (including also those lesional and extralesional samples obtained from patients with benign liver tumors) exhibited a PMR >4% which results in an overall 81.8% hypermethylation rate. The degree of methylation was significantly higher in samples from HCC compared to the non-cancerous liver tissue samples (63.10% vs. 24.98%; P = 0.001). Using an arbitrarily given PMR of 10%, 67% of non-cancerous liver samples were methylated, and using a PMR of 20 and 30%, only 47 and 20% of the 55 non-tumor tissues exhibited APC promoter methylation. Of particular interest was that all HCC samples exhibited a very high PMR above 20%. We found no association of APC methylation levels and age in any of the cancer patients in either tumor or non-tumor tissues.
###end p 43
###begin title 44
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
APC mutation analysis
###end title 44
###begin p 45
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 624 625 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 743 744 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 949 950 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1140 1146 1116 1122 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1296 1300 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1418 1423 1394 1399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1425 1427 1401 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1502 1503 1478 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1146 1527 1122 1503 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Western blot of the PTT analysis of the APC protein fragment II (aa1519 through aa1984). The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPC II) and the mutated shortened protein (trAPC II) are indicated on the <italic>right</italic>. <italic>WT</italic> protein, which was obtained by PTT analysis of non-mutated wild-type DNA, <italic>C</italic> DNA free control sample</p>
###xml 1146 1527 1122 1503 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Western blot of the PTT analysis of the APC protein fragment II (aa1519 through aa1984). The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPC II) and the mutated shortened protein (trAPC II) are indicated on the <italic>right</italic>. <italic>WT</italic> protein, which was obtained by PTT analysis of non-mutated wild-type DNA, <italic>C</italic> DNA free control sample</p></caption>
###xml 1527 1527 1503 1503 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig2_HTML" id="MO3"/>
###xml 1140 1527 1116 1503 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="46">Western blot of the PTT analysis of the APC protein fragment II (aa1519 through aa1984). The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPC II) and the mutated shortened protein (trAPC II) are indicated on the <italic>right</italic>. <italic>WT</italic> protein, which was obtained by PTT analysis of non-mutated wild-type DNA, <italic>C</italic> DNA free control sample</p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig2_HTML" id="MO3"/></fig>
###xml 1527 1533 1503 1509 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1655 1659 1631 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1775 1780 1751 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1853 1855 1829 1831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1533 1925 1509 1901 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">PTT analysis of four different clones of sample 4 in Fig. 2. The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPCII) and the mutated shortened protein (trAPCII) are indicated on the <italic>right</italic>. All clones show truncated proteins in addition to full length protein. <italic>WT</italic> protein, which was translated in vitro from non-mutated wild-type DNA</p>
###xml 1533 1925 1509 1901 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">PTT analysis of four different clones of sample 4 in Fig. 2. The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPCII) and the mutated shortened protein (trAPCII) are indicated on the <italic>right</italic>. All clones show truncated proteins in addition to full length protein. <italic>WT</italic> protein, which was translated in vitro from non-mutated wild-type DNA</p></caption>
###xml 1925 1925 1901 1901 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig3_HTML" id="MO4"/>
###xml 1527 1925 1503 1901 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="47">PTT analysis of four different clones of sample 4 in Fig. 2. The sizes of corresponding marker fragments are shown on the <italic>left</italic> in kilodaltons. The full-length protein (flAPCII) and the mutated shortened protein (trAPCII) are indicated on the <italic>right</italic>. All clones show truncated proteins in addition to full length protein. <italic>WT</italic> protein, which was translated in vitro from non-mutated wild-type DNA</p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig3_HTML" id="MO4"/></fig>
###xml 1925 1931 1901 1907 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1981 1992 1957 1968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</italic>
###xml 2181 2185 2157 2161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 2187 2198 2163 2174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</italic>
###xml 1931 2231 1907 2207 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Sequencing results of the APC gene from sample 4. <italic>Upper panel</italic>: chromatogram from forward sequencing and blast of the APC gene sequence (GenBank, accession number M74088) using the blast software (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">http://www.ncbi.nlm.nih.gov/BLAST/</ext-link>). The mutated nucleotide and amino acid are shown in <italic>bold</italic>. <italic>Lower panel</italic>: results from reverse sequencing</p>
###xml 1931 2231 1907 2207 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Sequencing results of the APC gene from sample 4. <italic>Upper panel</italic>: chromatogram from forward sequencing and blast of the APC gene sequence (GenBank, accession number M74088) using the blast software (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">http://www.ncbi.nlm.nih.gov/BLAST/</ext-link>). The mutated nucleotide and amino acid are shown in <italic>bold</italic>. <italic>Lower panel</italic>: results from reverse sequencing</p></caption>
###xml 2231 2231 2207 2207 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig4_HTML" id="MO5"/>
###xml 1925 2231 1901 2207 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="48">Sequencing results of the APC gene from sample 4. <italic>Upper panel</italic>: chromatogram from forward sequencing and blast of the APC gene sequence (GenBank, accession number M74088) using the blast software (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">http://www.ncbi.nlm.nih.gov/BLAST/</ext-link>). The mutated nucleotide and amino acid are shown in <italic>bold</italic>. <italic>Lower panel</italic>: results from reverse sequencing</p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig4_HTML" id="MO5"/></fig>
The mutation cluster region of the APC gene was amplified in two overlapping fragments. The PCR reactions led to products of the expected sizes in 11 of the 12 genomic DNAs (not shown). Sample 9 did not give any PCR product. The PCR products were used as templates in the in vitro transcription and translation reactions and the resulting proteins were analyzed by Western blot. All samples showed the full-length proteins I and II of the expected size of approximately55 kDa. Additionally, the analysis of protein II of sample 4 showed fragments, which were approximately5-10 kDa smaller than the full-length protein (Fig. 2). The PCR fragment of the sample was cloned. All tested clones showed truncated protein fragments in the PTT. Figure 3 shows the full length protein as a translation product of a wild type control and four different clones. The sequencing of the cloned fragments showed AGGGAT instead of the wildtype sequence AGGAAT (Fig. 4). The A to G transition was found in all tested clones by forward and reverse sequencing. The mutation leads to an alteration of the amino acid Glu to Gly at codon 1889 of the APC protein. Fig. 2Western blot of the PTT analysis of the APC protein fragment II (aa1519 through aa1984). The sizes of corresponding marker fragments are shown on the left in kilodaltons. The full-length protein (flAPC II) and the mutated shortened protein (trAPC II) are indicated on the right. WT protein, which was obtained by PTT analysis of non-mutated wild-type DNA, C DNA free control sampleFig. 3PTT analysis of four different clones of sample 4 in Fig. 2. The sizes of corresponding marker fragments are shown on the left in kilodaltons. The full-length protein (flAPCII) and the mutated shortened protein (trAPCII) are indicated on the right. All clones show truncated proteins in addition to full length protein. WT protein, which was translated in vitro from non-mutated wild-type DNAFig. 4Sequencing results of the APC gene from sample 4. Upper panel: chromatogram from forward sequencing and blast of the APC gene sequence (GenBank, accession number M74088) using the blast software (). The mutated nucleotide and amino acid are shown in bold. Lower panel: results from reverse sequencing
###end p 45
###begin p 46
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 279 281 279 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
Western blot of the PTT analysis of the APC protein fragment II (aa1519 through aa1984). The sizes of corresponding marker fragments are shown on the left in kilodaltons. The full-length protein (flAPC II) and the mutated shortened protein (trAPC II) are indicated on the right. WT protein, which was obtained by PTT analysis of non-mutated wild-type DNA, C DNA free control sample
###end p 46
###begin p 47
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 320 322 320 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
PTT analysis of four different clones of sample 4 in Fig. 2. The sizes of corresponding marker fragments are shown on the left in kilodaltons. The full-length protein (flAPCII) and the mutated shortened protein (trAPCII) are indicated on the right. All clones show truncated proteins in addition to full length protein. WT protein, which was translated in vitro from non-mutated wild-type DNA
###end p 47
###begin p 48
###xml 50 61 50 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</italic>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 256 267 256 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</italic>
Sequencing results of the APC gene from sample 4. Upper panel: chromatogram from forward sequencing and blast of the APC gene sequence (GenBank, accession number M74088) using the blast software (). The mutated nucleotide and amino acid are shown in bold. Lower panel: results from reverse sequencing
###end p 48
###begin title 49
Detection of APC protein expression in HCC and liver metastasis
###end title 49
###begin p 50
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 353 359 353 359 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 359 360 359 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 440 441 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 730 731 730 731 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 359 1063 359 1063 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51"><bold>a</bold> Western blot analysis of APC protein expression in three normal (<italic>N</italic>) and tumor (<italic>T</italic>) tissue samples obtained from three patients with hepatocellular carcinoma. Two isoforms of the APC protein (300 and 200&#160;kDa, respectively) were observed using antibodies directed against the APC protein. The sizes of corresponding marker fragments are shown on the <italic>right</italic> in kilodaltons. <bold>b</bold> Quantitative analysis of APC protein expression in hepatocellular cancer. The levels of APC expression in cancer and non-cancer tissues (the order of the patients is identical to the panel above) were standardized to the respective beta-actin expression levels. Overall no significant difference among the two isoforms was observed</p>
###xml 359 1063 359 1063 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51"><bold>a</bold> Western blot analysis of APC protein expression in three normal (<italic>N</italic>) and tumor (<italic>T</italic>) tissue samples obtained from three patients with hepatocellular carcinoma. Two isoforms of the APC protein (300 and 200&#160;kDa, respectively) were observed using antibodies directed against the APC protein. The sizes of corresponding marker fragments are shown on the <italic>right</italic> in kilodaltons. <bold>b</bold> Quantitative analysis of APC protein expression in hepatocellular cancer. The levels of APC expression in cancer and non-cancer tissues (the order of the patients is identical to the panel above) were standardized to the respective beta-actin expression levels. Overall no significant difference among the two isoforms was observed</p></caption>
###xml 1063 1063 1063 1063 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig5_HTML" id="MO6"/>
###xml 353 1063 353 1063 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="51"><bold>a</bold> Western blot analysis of APC protein expression in three normal (<italic>N</italic>) and tumor (<italic>T</italic>) tissue samples obtained from three patients with hepatocellular carcinoma. Two isoforms of the APC protein (300 and 200&#160;kDa, respectively) were observed using antibodies directed against the APC protein. The sizes of corresponding marker fragments are shown on the <italic>right</italic> in kilodaltons. <bold>b</bold> Quantitative analysis of APC protein expression in hepatocellular cancer. The levels of APC expression in cancer and non-cancer tissues (the order of the patients is identical to the panel above) were standardized to the respective beta-actin expression levels. Overall no significant difference among the two isoforms was observed</p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig5_HTML" id="MO6"/></fig>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 886 894 <span type="species:ncbi:9606">patients</span>
Next we investigated the APC protein expression in both tumor and corresponding non-neoplastic tissue samples obtained from patients with HCC (Fig. 5). By Western blot analysis two isoforms of the APC protein (200 and 300 kDa, respectively) were identified. We observed no quantitative differences in APC proteins levels in tumor and non-tumor samples. Fig. 5a Western blot analysis of APC protein expression in three normal (N) and tumor (T) tissue samples obtained from three patients with hepatocellular carcinoma. Two isoforms of the APC protein (300 and 200 kDa, respectively) were observed using antibodies directed against the APC protein. The sizes of corresponding marker fragments are shown on the right in kilodaltons. b Quantitative analysis of APC protein expression in hepatocellular cancer. The levels of APC expression in cancer and non-cancer tissues (the order of the patients is identical to the panel above) were standardized to the respective beta-actin expression levels. Overall no significant difference among the two isoforms was observed
###end p 50
###begin p 51
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 371 372 371 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
a Western blot analysis of APC protein expression in three normal (N) and tumor (T) tissue samples obtained from three patients with hepatocellular carcinoma. Two isoforms of the APC protein (300 and 200 kDa, respectively) were observed using antibodies directed against the APC protein. The sizes of corresponding marker fragments are shown on the right in kilodaltons. b Quantitative analysis of APC protein expression in hepatocellular cancer. The levels of APC expression in cancer and non-cancer tissues (the order of the patients is identical to the panel above) were standardized to the respective beta-actin expression levels. Overall no significant difference among the two isoforms was observed
###end p 51
###begin title 52
Immunohistochemical analysis of APC expression
###end title 52
###begin p 53
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1997</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1997</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1998</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 1075 1076 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1112 1118 1102 1108 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1618 1623 1608 1613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1687 1691 1677 1681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1118 1692 1108 1682 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54">Immunohistochemical expression of APC in liver and hepatocellular carcinomas. The distribution and expression pattern of APC in non-tumorous liver and HCCs was investigated by immunohistochemistry. Non-tumorous epithelium, and tumor were stained with two different anti-APC antibodies (anti-APC-N15 and anti-APC-C20). APC was found in the cytoplasm. In the majority of the patients studied, the intensity of immunostaining and the number of immunoreactive cells was decreased in tumorous epithelium (<italic>right</italic>) when compared with the corresponding non-tumorous epithelium (<italic>left</italic>)</p>
###xml 1118 1692 1108 1682 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54">Immunohistochemical expression of APC in liver and hepatocellular carcinomas. The distribution and expression pattern of APC in non-tumorous liver and HCCs was investigated by immunohistochemistry. Non-tumorous epithelium, and tumor were stained with two different anti-APC antibodies (anti-APC-N15 and anti-APC-C20). APC was found in the cytoplasm. In the majority of the patients studied, the intensity of immunostaining and the number of immunoreactive cells was decreased in tumorous epithelium (<italic>right</italic>) when compared with the corresponding non-tumorous epithelium (<italic>left</italic>)</p></caption>
###xml 1692 1692 1682 1682 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="432_2007_321_Fig6_HTML" id="MO7"/>
###xml 1112 1692 1102 1682 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="54">Immunohistochemical expression of APC in liver and hepatocellular carcinomas. The distribution and expression pattern of APC in non-tumorous liver and HCCs was investigated by immunohistochemistry. Non-tumorous epithelium, and tumor were stained with two different anti-APC antibodies (anti-APC-N15 and anti-APC-C20). APC was found in the cytoplasm. In the majority of the patients studied, the intensity of immunostaining and the number of immunoreactive cells was decreased in tumorous epithelium (<italic>right</italic>) when compared with the corresponding non-tumorous epithelium (<italic>left</italic>)</p></caption><graphic position="anchor" xlink:href="432_2007_321_Fig6_HTML" id="MO7"/></fig>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
###xml 1491 1499 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry was performed on paraffin-embedded sections from 14 patients with HCC. APC was found in the cytoplasm of each of the hepatocytes of non-tumorous liver parenchyma (14 patients), bile duct epithelium (Hiltunen et al. 1997), vascular smooth muscle cells (Hiltunen et al. 1997), and tumor cells (Behrens et al. 1998) (Fig. 6). The intensity of immunostaining and the number of immunoreactive cells were decreased in tumorous epithelium of 12 patients, when compared with the corresponding non-tumorous epithelium (Fig. 6). The expression of APC was similar in tumorous and non-tumorous epithelium of two patients. The difference between tumor cells, and non-tumorous hepatocytes was further quantified by determining the mean IRS values (+/- standard deviation). The non-tumorous hepatocytes showed a mean IRS with anti-APC-N15 of 4.5 +/- 1.0, and with anti-APC-C20 of 4.8 +/- 0.6, while in HCCs tumor cells showed a mean IRS with anti-APC-N15 of 3.0 +/- 1.5, and with anti-APC-C20 of 3.8 +/- 1.2. These IRS values reflect the overall significantly reduced (P < 0.05) expression of APC in HCCs. Fig. 6Immunohistochemical expression of APC in liver and hepatocellular carcinomas. The distribution and expression pattern of APC in non-tumorous liver and HCCs was investigated by immunohistochemistry. Non-tumorous epithelium, and tumor were stained with two different anti-APC antibodies (anti-APC-N15 and anti-APC-C20). APC was found in the cytoplasm. In the majority of the patients studied, the intensity of immunostaining and the number of immunoreactive cells was decreased in tumorous epithelium (right) when compared with the corresponding non-tumorous epithelium (left)
###end p 53
###begin p 54
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 569 573 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
Immunohistochemical expression of APC in liver and hepatocellular carcinomas. The distribution and expression pattern of APC in non-tumorous liver and HCCs was investigated by immunohistochemistry. Non-tumorous epithelium, and tumor were stained with two different anti-APC antibodies (anti-APC-N15 and anti-APC-C20). APC was found in the cytoplasm. In the majority of the patients studied, the intensity of immunostaining and the number of immunoreactive cells was decreased in tumorous epithelium (right) when compared with the corresponding non-tumorous epithelium (left)
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 10 13 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 220 224 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1998</xref>
###xml 668 671 656 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 730 734 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1997</xref>
###xml 748 752 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human APC gene product is part of a tetrameric complex, composed of conductin, a negative regulator of Wnt signaling, APC, GSK-3beta (serine-threonine glycogen synthase kinase 3beta) and beta-catenin (Behrens et al. 1998). The intact APC protein normally exerts an anti-tumor effect by forming a tetrameric complex, resulting in the accelerated degradation of beta-catenin and the inhibition of signal transduction to the lympoid enhancer factor-T cell factor (LEF-TCF) family of transcription factors. The truncated or functionally inactive APC protein which can result from (1) transcriptional silencing through promoter methylation, (2) a point mutation of the APC gene or (3) loss of heterozygosity (LOH) (Hiltunen et al. 1997; Chen et al. 2005) loses the ability to interact with beta-catenin, allowing the direct interaction of beta-catenin with LEF-TCF family of transcription factors and promoting cells to enter the cell cycle.
###end p 56
###begin p 57
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 295 299 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2001</xref>
###xml 375 378 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 575 579 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2002</xref>
###xml 691 694 688 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 761 765 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 779 783 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 800 804 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2005</xref>
###xml 960 964 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 978 982 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 1008 1011 1005 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1166 1170 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 1184 1188 1181 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 1205 1209 1202 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2005</xref>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 491 494 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 874 877 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 883 886 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
The clinical impact of transcriptional silencing of the APC gene induced by promoter methylation in HCC is currently unclear. A recent study showed that APC hypermethylation can disrupt the APC/beta-catenin pathway in primary liver cancer in one-third of the investigated cases (Esteller et al. 2001). In contrast, in an earlier report from China, the promoter region of the APC gene was found to be free of methylation both in tumor and non-tumor tissue samples obtained from patients with HBV-induced HCC using the same MSP method as reported in the first study (Yu et al. 2002). More recently, three groups used MSP or an MSP-based quantitative methylation analysis and reported that the APC promoter is methylated in 53-85% of patients with HCC (Lee et al. 2003; Yang et al. 2003; Lehmann et al. 2005). A particularly high frequency of promoter methylation was found in HCV- and HBV-related HCCs affecting 80 and 55% of the cases, respectively (Lee et al. 2003; Yang et al. 2003). The CpG islands of the APC promoter were methylated in up to 27% of patients with liver cirrhosis and in 14-32% of liver tissue samples without any pathological changes (Lee et al. 2003; Yang et al. 2003; Lehmann et al. 2005).
###end p 57
###begin p 58
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1A</italic>
###xml 260 263 260 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 516 519 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
In our study, the MethyLight analysis, a novel method for epigenetic studies was used. It provides a more sensitive tool for detecting promoter methylation and also allows quantitative assessment of methylation. We demonstrate a high-methylation rate of the 1AAPC promoter: 81.8% of the non-cancerous liver tissue samples exhibited a PMR >4%. Even when a significantly higher methylation rate of 20% was used, 47% of samples remained methylated. The (patho) physiological function and significance of the methylated APC promoter in the non-malignant liver tissue samples is unclear.
###end p 58
###begin p 59
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2005</xref>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 437 440 437 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 543 546 543 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 701 704 701 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 926 930 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2000</xref>
###xml 937 940 937 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1128 1131 1128 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1517 1520 1517 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 92 97 <span type="species:ncbi:9606">women</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 1478 1486 <span type="species:ncbi:9606">patients</span>
The APC promoter has also been reported to be methylated in normal breast tissue samples of women at high risk for breast cancer in 56% of cases (Lewis et al. 2005). About 97.5% of patients with non-cancerous gastric mucosa also exhibited APC promoter methylation and this was considered-in contrast to the colon (Chen et al. 2005)-a normal event (Tsuchiya et al. 2000). However, the function and clinical significance of the methylated APC promoter in normal tissue and normal mucosa has not been addressed in the past. The high frequency of APC promoter methylation in non-cancerous liver parenchyma as observed in our study may be explained in different ways. (1) A low level of methylation of the APC promoter occurs physiologically in the liver, and may have been missed by previous investigation, simply because the Methylight assay used herein is far more sensitive than the MSP protocol applied by others (Eads et al. 2000); (2) APC promoter methylation in non-tumorous liver parenchyma may result from methylation field effects in the chronically inflamed, fibrotic liver, which bears the risk of developing HCC. Thus, APC promoter hypermethylation may precede the development of histologically overt lesions, such as dysplastic nodules, small cell dysplasia or HCC, none of which were studied in our non-lesional tissue samples. However, non-tumorous liver parenchyma without evidence of chronic inflammation, fibrosis or cirrhosis (in our study samples obtained from patients with liver metastases) showed APC promoter methylation which supports the first interpretation. Further studies are clearly needed to resolve this very interesting issue in epigenetic studies.
###end p 59
###begin p 60
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 216 219 216 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 670 673 670 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1004 1007 1004 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
The 1A promoter region of the APC gene was found to be methylated in all tissue samples from patients with HCC using the 4% PMR, and all samples remained methylated at a PMR of 20%. Our findings indicate that the 1A APC promoter is generally methylated in the liver suggesting that this epigenetic change is not specific for hepatocarcinogenesis and is not related to chronic hepatitis virus infection as reported in the previously published studies (Lee et al. 2003; Yang et al. 2003), because all tissue samples investigated in our study were obtained from patients with non-hepatitis virus-related HCC. It was of particular interest that the methylation grade of the APC promoter was significantly enhanced in the HCC samples compared with that of the corresponding non-tumor samples. These findings suggest that quantitative epigenetic changes are probably of clinical significance in hepatocarcinogenesis, but further post-transcriptional mechanisms must also be responsible for inactivation of the APC gene in HCC.
###end p 60
###begin p 61
###xml 14 17 14 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 151 154 151 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 593 596 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 731 735 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">1997</xref>
###xml 871 874 871 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 219 226 <span type="species:ncbi:9606">patient</span>
While somatic APC gene mutations are prevalent in some gastrointestinal tumors such as colorectal cancer (Chen et al. 2005), HCC usually do not harbor APC mutations. In our series, an APC mutation was found in only one patient (8%). The mutation, however, which was found and confirmed in this sample did not cause a stop codon and the sequencing results excluded non-sense or frameshift mutations caused by the Taq polymerase. Nevertheless, the detected transition might be the reason for the truncated proteins which were detected in the PTT. A mutation in a similar repetitive motif of the APC gene reported by Laken et al. was shown to lead to truncated proteins in the PTT in addition to the full length protein (Laken et al. 1997). The authors explained this finding by failures in the transcriptional or translational machinery caused by the mutation. In summary, APC gene mutations do not seem to play an important role in the inactivation of APC in HCC.
###end p 61
###begin p 62
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2001</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2002</xref>
###xml 275 278 275 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
Previous studies focused on epigenetic changes of the APC promoter but did not evaluate the APC protein expression in HCC (Lee et al. 2003; Yang et al. 2003; Esteller et al. 2001; Yu et al. 2002). Therefore, in our analysis, we assessed the impact of promoter methylation of APC on protein expression in HCC and non-tumor tissue samples. Using Western blot analysis, both isoforms of the APC protein were shown to be present indicating that APC protein is expressed in primary liver cancer cells. In order to further evaluate subcellular expression of the APC protein, immunohistochemistry with a numerical scoring system allowing semiquantitative analysis of the expressed protein was applied. The APC protein was expressed both in non-tumor and tumor tissue samples obtained from patients with HCC, but values derived from our IRS were significantly lower in HCC samples compared with that of non-cancerous liver tissue samples. This finding reflects the overall reduced expression of the APC protein in patients with HCC.
###end p 62
###begin p 63
###xml 99 102 99 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 354 357 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 742 745 742 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 876 879 876 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
In conclusion, using a highly sensitive tool for detecting epigenetic changes, we demonstrate that APC promoter methylation is a very frequent epigenetic change in patients with HCC. Furthermore, we show that methylation of the APC promoter is also present in the vast majority of the non-tumorous liver tissue samples, indicating that this low level of APC methylation is universally present in the liver cells and is not a specific marker of liver carcinogenesis and is probably not induced by hepatitis virus infection. Because promoter methylation is significantly enhanced in HCC compared to that of non-tumor samples, and APC expression is also significantly reduced in liver cancer cells, higher degrees of promoter methylation of the APC gene seem to be responsible for the reduced APC protein expression in HCC. The pathophysiological function of the hypermethylated APC promoter in non-tumor liver cells deserve further studies to resolve this important issue.
###end p 63
###begin p 64
M. P. Ebert is supported by the a grant from the DFG (187/4-1) and the Heisenberg-Programme (Eb 187/5-1). A. Csepregi is supported by the "Rotationsprogramm" of the NBL-3 of the BMBF.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta
###end article-title 66
###begin article-title 67
The essentials of DNA methylation
###end article-title 67
###begin article-title 68
Epidemiology of primary liver cancer
###end article-title 68
###begin article-title 69
Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis
###end article-title 69
###begin article-title 70
Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
###end article-title 70
###begin article-title 71
Loss of beta-catenin expression in metastatic gastric cancer
###end article-title 71
###begin article-title 72
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 72
###begin article-title 73
###xml 12 38 12 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adenomatous polyposis coli</italic>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
###end article-title 73
###begin article-title 74
###xml 29 55 29 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adenomatous polyposis coli</italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma
###end article-title 74
###begin article-title 75
Histological grading and staging of chronic hepatitis
###end article-title 75
###begin article-title 76
A non-radioactive protein truncation test for the sensitive detection of all stop and frameshift mutations
###end article-title 76
###begin article-title 77
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
###end article-title 77
###begin article-title 78
Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis
###end article-title 78
###begin article-title 79
Distinc methylation pattern of benign and malignant liver tumors revealed by quantitative methylation profiling
###end article-title 79
###begin article-title 80
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk
###end article-title 80
###begin article-title 81
Hepatocellular carcinoma
###end article-title 81
###begin article-title 82
Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia
###end article-title 82
###begin article-title 83
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma
###end article-title 83
###begin article-title 84
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis
###end article-title 84
###begin article-title 85
###xml 15 41 15 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adenomatous polyposis coli</italic>
Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype
###end article-title 85

